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ABBREVIATIONS 
 
AII  Angiotensin II 
ABPM  Ambulatory Blood Pressure Monitoring 
ASE  American Society of Echocardiography 
BNP  B-type natriuretic peptide 
BSA  Body surface area  
BMI  Body mass index 
BP  Blood pressure 
CABG  Coronary artery bypass graft 
CAD  Coronary artery disease 
ECG  Electrocardiogram 
LV  Left ventricular 
LVH  Left ventricular hypertrophy 
LVM  Left ventricular mass 
LVMI  Left ventricular mass index 
LVEF  Left ventricular ejection fraction 
IVS  Interventricular septal wall thickness 
LVIDD Left ventricular internal diameter during diastole 
MI  Myocardial infarction 
PCI  Percutaneous coronary intervention 
PWT  Posterior wall thickness 
RWT   Relative wall thickness 
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Abstract 
 
Objectives: To assess the prevalence of left ventricular hypertrophy (LVH) in 
patients with newly diagnosed peripheral arterial disease (PAD). 
 
Methods: Consecutive patients referred for the first time for assessment of 
PAD with a history of intermittent claudication and ankle brachial pressure of 
index of ≤0.9 were recruited. All subjects underwent a full echocardiogram, 
office blood pressure and 24 hour ambulatory blood pressure monitoring.  
 
Results: Out of 350 subjects screened, left ventricular mass measurements 
were available on 227 (65%). The prevalence of LVH indexed to body 
surface area was 50%. In a multiple regression model the factors 
independently related to LVH were age, sex and history of diabetes. There 
was no relation between presence of LVH and 24 hour blood pressure. 
 
Conclusion: LVH is prevalent in patients with PAD and is not associated 
with 24 hour blood pressure. 
 8 
Papers!arising!from!this!Research!
!
Wright!GA,!And!DS,!Stonebridge!PA,!Belch!JJ,!Struthers!AD.!Left!ventricular!hypertrophy!is!present!in!one!half!of!newly!disagnoses!peripheral!arterial!disease!patients.!Journal(of(
Hypertension,(2007;(25(2):463=469(!Ang!DS,!Fahey!TP,!Wright!GA,!Struthers!AD.!Development!and!validation!of!a!clinical!score!to!identify!echocardiographic!left!ventricular!hypertrophy!in!patients!with!cardiovascular!disease.!American(Journal(of(Hypertension.(2008;21(9):1011=
1017
 9 
HYPOTHESIS 
 
Peripheral Arterial Disease (PAD) is a common condition, affecting 
approximately 3 to 25% of the population and this group of patients are 
known to be at high risk of premature death (1-6). It is generally thought that 
this is exclusively due to coincidental coronary artery disease, which leads to 
cardiac death due to ischaemic events. While this is likely to be a major 
factor, left ventricular hypertrophy (LVH) is potentially a second major 
contributor to cardiac death in these patients but little attention is routinely 
paid to this added risk factor (7). LVH is an important predictor of 
cardiovascular risk and studies in the comparable vascular disease of angina, 
suggest that left ventricular hypertrophy poses a bigger risk of cardiac death 
than multivessel coronary disease with a relative risk of 2.4 for LVH and 1.6 
for multivessel coronary artery disease (CAD) (7).   
 
LVH is known from all population studies to be a strong independent risk 
factor for cardiovascular death but what we do not yet know is how common 
LVH is in PAD patients (8-12). To have a significant impact on a condition, 
the risk factor should be common. There are several reasons to believe that 
LVH might be common in PAD paients.  
 
Firstly, by its nature, PAD is associated with stiff arteries, which increases 
left ventricular (LV) afterload and in theory promotes LVH.  
 
 10 
Secondly, in patients of similar high cardiovascular risk, data shows that LVH 
is remarkably common. Data from this institution (University of Dundee) 
demonstrated that 52% of angina patients, 42% of type 2 diabetics, 25% in a 
random group of stroke survivors and 25% in a random group of patients 
attending a geriatric day hospital have evidence of LVH (13, 14).   
 
Thirdly, PAD patients have an increased incidence of renovascular disease 
(overt and subclinical) which increases Blood Pressure (BP) and thereby 
promotes LVH.  
 
Fourthly, often a vascular surgeon is the only specialist to see a PAD patient 
and they may understandably focus more on surgical possibilities than on the 
pharmacological management of these patients BP or secondary 
cardiovascular protection.  
 
If LVH does turn out to be common in PAD patients, then detecting and 
treating it could be a major new way to reduce cardiac deaths in this group of 
with high mortality and morbidity.  This possibility arises because LVH 
regression has been shown to strongly improve prognosis, irrespective of BP 
changes (15). Indeed, it appears that full LVH regression returns risk to that 
of someone with no LVH (12, 16). 
In this study I set out to assess how LVH is prevalent in PAD patients and to 
elucidate its relation to blood pressure. 
 !
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1.1 PERIPHERAL ARTERIAL DISEASE 
1.1.1 DEFINITION AND PREVALENCE 
The American Heart Association/ American College of Cardiology 
(AHA/ACC) 2005 Practice guidelines for the management of patients with 
peripheral arterial disease state: “The term “peripheral arterial disease” 
includes a diverse group of disorders that lead to progressive stenosis or 
occlusion, or aneurysmal dilation, of the aorta and its non-coronary branch 
arteries, including the carotid, upper extremity, visceral, and lower extremity 
arterial branches.” (17) 
 
Historically, the term “peripheral vascular disease” has been most used to 
describe the noncardiac diseases that affect the circulation as a whole. This 
term encompasses numerous pathophysiological syndromes that affect the 
arterial, venous, and lymphatic circulations. It therefore includes all vascular 
diseases that alter organ perfusion. Arterial diseases include those disorders 
that cause either fixed obstruction or abnormal vascular reactivity of the 
arterial supply to a given tissue. This can lead to impaired blood delivery and 
produce ischemia. 
 
PAD is very common in the western world and a recent systematic review of 
the literature demonstrated that contrary to common belief, it is just as 
common in low and middle income countries than in the more affluent parts 
of the world (6). Estimates of the prevalence of peripheral arterial disease 
vary widely, from 3% to 57%, depending on how the disease is identified and 
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the populations studied (2, 5, 6, 18-34). PAD is just as common in females as 
it is in males; indeed it is more prevalent in females in some age groups 
compared to their male counterparts. In both sexes the prevalence increases 
from 2.7% in those aged 25 to 29 years to 24% in those aged above 95 years 
in the same proportion in high income countries (HIC) (6). In low and middle-
income (LMIC) countries the prevalence increases from 1.2% in males and 
4% in females at age 25 to 29 years to 21.5% in males and 18.6% in females 
at age over 95 years. The prevalence of PAD in females from age 25years to 
64 years is approximately double that of their male counterparts in low and 
middle-income countries. Rates of newly diagnosed disease are in the range 
of 7% to 13% per year (28). The proportion of people with PAD has increased 
by up to 50% worldwide, with most of this increase occurring in low and 
middle-income countries (6). PAD can be progressive, with about a third of 
patients reporting worsening symptoms that require surgical interventions 
over 5 to 10 years (17).  
 
1.1.2 PATHOGENESIS AND RISK FACTORS FOR PAD 
 
PAD typically refers to the atherosclerotic process that involves the lower 
extremities, commonly the aorta and ilio-femoral arteries. Atherosclerosis is a 
complex process involving vascular remodeling, inflammation, oxidative 
stress, thrombosis, platelet aggregation, lipid abnormalities and endothelial 
disturbance. Similar to the analogous process of coronary atherosclerosis, this 
process involves a number of stages including lesion initiation with 
endothelial dysfunction, fatty streak development, fibroproliferative 
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atheroma, lipid rich core with fibrous cap and intimal hyperplasia. This causes 
remodeling and intrusion into the lumen of the artery causing claudication 
(angina of the leg muscles). Claudication symptoms occur due to mismatch 
between oxygen requirements and delivery to the skeletal muscles of the 
lower limbs. This process is usually insidious but the presence and severity of 
symptoms can be related to other factors. These factors include endothelial 
function, collateral blood supply, oxygen delivery, muscle mechanics and 
energy metabolism and patient comorbidities. Acute occlusions occur when 
there is disruption of the fibrous cap, resulting in exposure of the necrotic 
lipid rich core and subendothelial tissue resulting in thrombus formation and 
acute ischaemia.  
 
PAD is a marker for generalized systemic atherosclerosis and it has typical 
cardiovascular risk factors such as advanced age, cigarette smoking, diabetes 
mellitus, hypercholesteroaemia, and hypertension (6). In addition to age with 
an odds ratio of 1.39, several risk factors showed a consistently significant 
association with PAD in both HIC and LMIC. Smoking was the strongest risk 
factor with an OR of 2.1 for all countries, and diabetes a close second with an 
OR of 1.68. Almost every study on PAD has reported an important link with 
hypertension, with 50% to 92% of subjects having a history of arterial 
hypertension (5, 27). The Framingham study demonstrated a 2.5 to 4-fold 
increase in the risk of developing PAD in subjects with hypertension (35).  
 
As well as the traditional cardiovascular risk factors, other factors have been 
demonstrated to be important in PAD such as race and ethnicity, genetics and 
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abnormal hip to waist ratios (Table 1.1). There are well-recognized 
differences in cardiovascular disease in different ethnic groups. Although 
South Asians living in the UK have a worse risk factor profile and greater risk 
of coronary artery disease than the Caucasian population, they have a lower 
prevalence of PAD and lower limb amputation rates (36, 37). Caucasians 
have a higher incidence of abdominal aortic aneurysm. The reason for this 
discrepancy is not clear and it is not know whether PAD disease distribution 
is due to genetic or environmental differences. It is known that South Asians 
have a higher mortality from CAD than the Caucasian population and it may 
be that South Asians don’t live long enough to develop symptomatic PAD; 
given that PAD is strongly associated with age (37). To date, no major gene 
has been discovered for PAD, although observational studies suggest an 
increased rate amongst healthy relatives of patients with claudication (38). 
 
Table1.1 Risk Factors for Peripheral Arterial Disease 
Traditional Non-Traditional 
Advanced Age Race/Ethnicity 
Smoking Genetics 
Diabetes & Impaired Glucose 
Tolerance 
Inflammatory Markers (CRP, 
Fibrinogen, IL-6) 
Hypertension Hypercoagulable States 
Dyslipidaemia Abnormal hip to waist ratio 
 Homocysteine 
 Chronic Kidney Disease 
 Metabolic Syndrome 
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1.1.3!PROGNOSIS!OF!PAD!(MORTALITY!AND!MORBIDITY)!
 
Compared to the large publicity and public health initiatives on myocardial 
infarctions (MIs) and strokes, public recognition of the risks, symptoms, 
morbidity and mortality associated with PAD has been largely neglected. A 
number of studies suggest that risk factor management is treated less 
aggressively in those patients with PAD as opposed to those with CHD (5, 
39). The prevailing evidence shows that PAD is a worldwide disease and its 
prevalence has increases by almost 50% over the last 10 years. This 
represents a significant public health problem, given the increased mortality 
and morbidity associated with PAD (40, 41). 
 
PAD is strongly associated with age and has the same traditional 
cardiovascular risk factors as MI and stroke. The prevalence of coronary heart 
disease in patients with PAD is between 14% and 90%, depending on the 
population screened and tests used (2, 30, 42-44). The prevalence of 
cerebrovascular disease varies just as wildly. Depending on how it is 
quantified it ranges from less than 20% in those diagnosed from symptoms to 
80% in those with a stenosis of a major head and neck artery of >30% (3, 4, 
21, 22, 27, 34, 45-47).  
A large retrospective study performed in Canada over a 10-year period from 
1985 to 1995, demonstrated that the annual mortality was higher among 
patients with symptomatic PAD (8.2%) than those with a prior myocardial 
infarction (6.3%) (28). The investigators compared outcomes of the PAD 
 17 
cohort (16,440 patients) to reference populations with a first diagnosis of 
myocardial infarction (15,590 patients) and stroke (18,704 patients). 10% of 
the PAD population suffered a subsequent stroke, a further 10% had an MI 
and almost half were dead (49%) within the mean follow-up of 5.9 years. 
This compares to a mortality rate of 40% in the MI group and 49% in the 
stroke group. Broadly similar findings have also been reported in previous 
studies involving patients with PAD symptoms (32, 46, 48-52). This 
compares impressively with a recent meta analysis of four large 
cardiovascular trials in post MI and heart failure patients (CAPRICORN, 
VALIANT, EPHESUS and OPTIMAAL) (53). In this meta analysis 28,771 
patients were analyzed with a PAD prevalence of 8.2%. Over a mean follow 
up of 2.7 years 18.8% of these patients died and 52.3% experienced a 
composite of cardiovascular death or hospitalization. In patients with PAD the 
adjusted HR for heart failure hospitalization was 1.37 and all cause mortality 
of 1.26 (53). The model controlled for the following covariates: age, gender, 
race, systolic blood pressure, BMI, smoking history, Killip class, history of 
diabetes, hypertension, angina, MI, Atrial fibrillation, dyslipidaemia, renal 
insufficiency, heart failure, chronic obstructive pulmonary (COPD) and 
stroke. Even adjusting for all these factors, PAD was strongly associated in a 
multivariate model, with all cardiovascular morbidity including, CV 
hospitalizations, heart failure, MI, and all composite endpoints with an 
adjusted HR of between 1.17 and 1.52. The strongest association was with 
subsequent MI. Surprisingly; the only CV endpoint that was not statistically 
increased in a multivariate model was that of stroke, although it was in a 
univariate model. These figures are consistent with other studies, including 
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the Global Registry of Acute Coronary Events (GRACE), where the 
prevalence of PAD was 9.7% in 41,108 participants with acute coronary 
syndrome (54). 
The increase in cardiovascular risk in those with PAD was dependent on the 
number of additional risk factors at the time of diagnosis, illustrating how risk 
factors are additive, resulting in a 'cumulative' cardiovascular risk that 
parallels cardiac disease. The risk of myocardial infarction was significantly 
increased in those aged over 65 years, especially with concomitant angina, 
diabetes mellitus, heart failure, and hypertension. 
Having PAD confers high cardiovascular risk, which is comparable to 
populations of patients with prior MI and stroke, and this message needs to be 
emphasized. Importantly, the majority of PAD subjects remain asymptomatic 
but constitute a high-risk population. Of concern, risk factor reduction in 
those with a diagnosis of PAD is less frequently applied in comparison to 
those with cardiac disease. Thus, PAD patients may have had a less intensive 
risk reduction, leading to an increased cardiovascular event rate. 
PAD commonly presents in secondary care to vascular surgeons in the UK 
and the onus is on them to initiate full cardiovascular risk prevention 
therapies, such as smoking cessation and the aggressive treatment of 
hypertension and lipids. However, many PAD patients also have cardiac 
problems, and may attend hypertension and lipid clinics. Perhaps the time has 
come to organise vascular clinics jointly run by vascular surgeons and 
cardiovascular physicians, as one possible solution. The approach to the PAD 
patient should not simply be surgical but should include intense focus on 
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aggressive risk factor identification and modification (5, 17, 31, 51, 55, 56). 
As in cardiac disease, blockade of the renin-angiotensin-aldosterone system 
(RAAS) may offer another therapeutic target. For example, in the Heart 
Outcomes Prevention Evaluation (HOPE) study, 44% of the study population 
(patients at high risk of cardiovascular events including patients with 
cardiovascular disease, diabetes and age >55 years) had PAD and an 
impressive reduction in cardiovascular events was seen in the ACE inhibitor 
(Ramipril) group. This reduction was independent of blood pressure reduction 
(57). 
In summary, there is now growing evidence that PAD patients are a high-risk 
group, although still relatively under detected and under treated. This is 
despite the fact that they have an increased mortality rate comparable to those 
with pre-existing or established cardiovascular disease (myocardial infarction, 
stroke).  
 
1.1.4 MANAGEMENT OF PERIPHERAL ARTERIAL 
DISEASE 
 
The importance of risk factor management in patients with PAD is less well 
appreciated compared to those patients with coronary artery or cerebro-
vascular disease and is treated less aggressively. The Scottish Intercollegiate 
Guidelines Network (SIGN) and National Institute for Health and Clinical 
Excellence (NICE) guidelines mandate that patients with PAD should be seen 
in a cardiovascular clinic and have a cardiovascular risk factor assessment. 
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The overall management in this group of patients involves reducing 
cardiovascular events through risk factor optimization, preventing progression 
of PAD and limb loss and improving symptoms and general wellbeing 
thorough counseling, pharmacological medication, exercise programs and 
surgery or vascular endovascular intervention where required.  
 
1.1.4.1 Blood Pressure Optimization 
Hypertension is an established risk factor for mortality and morbidity and that 
adequate treatment reduces cardiovascular risk in the population. Blood 
pressure control in PAD patients is supported by the Heart Outcome 
Prevention Evaluation study (57). The ACE inhibitor Rampril resulted in a 
20% relative risk reduction in MI, Stroke and vascular death. Beta blocker 
therapy is advocated in patients with coronary disease and there is no 
evidence of worsening of claudication in patients with PAD, despite previous 
historical concerns regarding this side effect (58). 
 
1.1.4.2 Anti-platelet Therapy 
The antiplatelet agent Aspirin has been strongly advocated in all guidelines. 
Aspirin may reduce the occurrence of acute cardiovascular events by 
decreasing the risk of thrombus formation. A meta analysis performed by the 
Antithrombotic Trialists’ Collaboration demonstrated a significant benefit 
from daily anti-platelet agent use in patients at high cardiovascular risk. In a 
subgroup analysis of PAD patients, there was a statistically significant 23% 
reduction in major vascular events in the group taking anti-platelet therapy 
(59). A recent randomized controlled trial assessing the efficacy of low dose 
 21 
aspirin in patients with PAD demonstrated a 26% reduction in vascular events 
compared to patients not taking aspirin (60). In a subgroup analysis of the 
CHARISMA trial, dual anti-platelet therapy with the combination of aspirin 
and clopidogrel versus aspirin alone showed no benefit in the composite end 
point of MI, stroke and CV events (61). Therefore, single agent anti-platelet 
agents are recommended for prevention of CV events in patients with PAD. 
 
1.1.4.3 Lipid Lowering Therapy 
The use of lipid lowering therapy and in particular, HMG-CoA reductase 
inhibitors (Statins) such as Simvastatin and Atorvastatin, has been associated 
with a significant improvement in outcome in primary and secondary 
cardiovascular patients. Less is known about the benefit of these agents in 
patients with peripheral arterial disease compared to the extensively studied 
group of patients with cardiovascular and cerebrovascular disease. A 
subgroup analysis of PAD patients in the Heart Protection Study 
demonstrated a 22% relative risk reduction in the rate of first major vascular 
events in the group taking Simvastatin, regardless of baseline LDL level (62). 
Moreover, there is evidence that these agents improve symptoms of 
claudication and increase walking distance (63). Therefore, lipid lowering 
with a statin is recommended for patients with PAD and a total cholesterol of 
>3.5mmol/l.  
!
1.1.4.4 Smoking Cessation 
Smoking is one of the most potent risk factors for the development of PAD. It 
has a 2 to 6-fold increase in the risk of developing PAD with a dose-response 
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effect (64). Patients who smoke also have a worse outcome, with higher rates 
of critical limb ischaemia and amputation. Smoking cessation improves 
survival and improves exercise capacity; this is evident even after 1-year of 
abstinence (65). Smoking cessation is therefore at the foundation of risk 
reeducation in this group of patients.   
 
 
1.1.4.5 Exercise Therapy 
Patients with symptomatic PAD have reduced exercise capacity and quality of 
life. Supervised exercise programs have consistently been shown to improve 
walking performance, claudication severity and quality of life. A Cochrane 
review and meta analysis of trials comparing supervised and unsupervised 
exercise therapy in patients with symptomatic PAD showed that supervised 
exercise produced significant improvements in walking distance of between 
60% to 337%, compared to unsupervised exercise (66). Therefore, in all 
guidelines, patients with PAD and intermittent claudication should be 
encouraged to partake in supervised exercise. 
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1.1.4.6 Summary 
PAD is an under diagnosed and undertreated condition and is associated with 
a profound increase in mortality and morbidity. Claudication is a marker of 
systemic atherosclerosis which mandates aggressive risk factor management 
and intensive medical therapy. This is not always achieved in the primary or 
secondary care setting. The therapeutic interventions that should be 
implemented include: 
Antihypertensive Therapy 
Lipid Lowering Therapy 
Antiplatelet Agents 
Smoking cessation 
Supervised Exercise Therapy 
 
 
These measures not only improve symptoms and quality of life but also 
significantly reduce cardiovascular events. 
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1.2 PATHOGENESIS OF LEFT VENTRICULAR 
HYPERTROPHY 
1.2.1 PATHOPHYSIOLOGY 
Left Ventricular Hypertrophy (LVH) is thought to be a structural adaptation 
of the heart, at least in part, as a compensatory mechanism for increased blood 
pressure and wall stress (i.e. increased mechanical load such as increased 
blood pressure and aortic stenosis) (67). 
The heart is able to compensate for haemodynamic burden by: 
1) Using the Frank-Starling mechanism to increase 
contractility 
2) Employing hormonal mechanisms to increase contractility 
3) Increasing muscle mass to bear the extra load 
 
The first mechanism is limited physiologically and the second has been shown 
to be deleterious chronically, such as in heart failure. Increasing cardiac 
muscle mass has a key compensatory role in haemodynamic overload. This 
increase in mass is due to hypertrophy (increase in size) rather than 
hyperplasia (increase in number) of cardiac myocytes. Cardiac muscle 
hypertrophy is the chronic adaptation of the left ventricle to increased cardiac 
load. Increased wall stress provides a stimulus for increased mRNA 
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transcription of myocyte proteins. Studies performed on the pathways that can 
lead to the increased protein synthesis that causes LVH have provided 
evidence that LVH may occur in the absence of recognisable changes in 
cardiac loading conditions (68-70).   
 
It is believed that mechanical signals initiate a cascade of biological events 
leading to cardiac growth and hypertrophy. Hypertrophy is usually 
accompanied by complex changes in gene expression. These changes include 
the re-expression of immature foetal cardiac genes, variable expression of 
genes that modify intracellular ion homeostasis and important parasympathetic 
and sympathetic receptors are down regulated (e.g. down regulation of α1-
adrenergic receptors, M2 muscarinic receptors and increase in ratio of 
angiotensin-II AT2 to AT1 receptor subtypes). However, the long-term 
implications of these changes in gene expression are still unclear in vivo (68-
71). 
After birth, the myocytes lose their ability to proliferate (increase their 
numbers). Subsequent growth therefore occurs as a result of enlargement of 
preexisting myocyte cells. Myocardial gene expression is up regulated in the 
initiation of ventricular hypertrophy, although the precipitating factors 
involved in this up regulation are not well understood. A number of molecular 
risk factors for hypertrophy including modulation of the renin-aldosteone-
angiotensin system (RAAS), growth factors, natriuretic peptides, endothelin, 
and the cardiac myosin heavy chain genes have been reported (68-71). 
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Hypertension has long been implicated as one of the most important 
underlying causes of LV hypertrophy. Other factors implicated include: 
• obesity,   
• age,   
• dietary sodium intake,   
• volume load,   
• diabetes,   
• arterial hypertrophy and stiffening (pressure overload),  
•  insulin resistance, and   
• neurohumoral factors (e.g., adrenergic factors and the renin-
angiotensin-aldosterone system).  
Many of these factors differ across ethnic groups, and may partially account 
for the observed differences in LV hypertrophy across populations. Given the 
number of potential determinants of LV hypertrophy, there are likely to be 
several genes acting independently or synergistically to increase risk for LV 
hypertrophy. 
1.2.2 SIGNALS FOR CARDIAC GROWTH 
The search for a chemical signal that serves as a master switch for cardiac 
growth has so far proved fruitless. Multiple kinases that are implicated in 
hypertrophy are located within the extracellular matrix (ECM) of cardiac 
myocytes. It appears that angiotensin II, via the AT1 receptor, plays a crucial 
role in the induction of hypertrophy as this hormone can induce the molecular 
events of early cardiac growth in mammals (68, 69, 71). However, the 
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observation that pressure overload produces cardiac hypertrophy in AT1 
receptor knock-out mice suggests that there are other important mechanisms. 
The pathways through which different stimuli increase LV mass are unknown 
but likely involve expression of numerous genes and cardiac transcription of 
neorohormones including angiotensin-II, aldosterone and endothelin (72, 73). 
Neurohormones have both haemodynamic activity (e.g. increase blood 
pressure, reduce sodium excretion) and are direct growth factors. Studies 
suggest that the process of hypertrophy begins at the time of increased 
mechanical strain and progresses through its compensatory stage to a 
pathological stage leading to an increase in LV mass, which is deleterious. It is 
clear that the signals involved in the initiation and perpetuation of ventricular 
hypertrophy are complex and not well understood. It is beyond the scope of 
this thesis to discuss in detail, the molecular and genetic basis for left 
ventricular hypertrophy. 
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1.2.3 LVH AND PRESSURE AND VOLUME OVERLOAD 
1.2.3.1 PRESSURE OVERLOAD 
In response to pressure overload in conditions such as aortic stenosis or 
peripheral arterial hypertension, the parallel addition of sarcomeres causes an 
increase in myocyte width (not number), which in turn increases wall 
thickness. This remodeling results in concentric hypertrophy (increase in ratio 
of wall thickness/chamber dimension).  
A principle of physics is that the tension on the wall of a sphere is the product 
of the pressure times the radius of the chamber and the tension is inversely 
related to the thickness of the wall.  
 
According to the law of LaPlace, the load on the myocardium is given as 
follows:  
 
Pressure x Radius 
 Wall Thickness 
 
Therefore, an increase in pressure can be offset by an increase in wall 
thickness.  
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1.2.3.2 VOLUME OVERLOAD 
 
Volume overload in conditions such as chronic aortic valve regurgitation, 
mitral valve regurgitation, anemia or renal failure, creates myocyte 
lengthening by sarcomere replication in series and therefore an increase in 
ventricular volume (74, 75). This pattern of eccentric hypertrophy (cavity 
dilatation with a decrease in ratio of wall thickness/chamber dimension) is 
also initially compensatory. The heart can meet the demand to sustain a high 
stroke volume. However, chronic hypertrophy may be deleterious because it 
increases the risk of developing heart failure and consequently premature 
death (76). 
 
1.2.4 HYPERTROPHY AND CONNECTIVE TISSUE 
 
For myocyte growth to support an increased mechanical load, it must be 
accompanied by increases in the surrounding extra cellular matrix architecture 
of connective tissue and ground substance, as well as the capillary and nerve 
networks. The connective tissue itself is primarily composed of collagen with 
smaller amounts of elastin, laminin, and fibronectin. Although collagen types 
I, III, and V are found in the myocardium, type I comprises 85% of the total 
collagen in this location. The complex collagen weave provides a mechanism 
for translating individual myocyte force generation into ventricular 
contraction, it controls the development of cardiac interstitial edema, and it is 
responsible for much of the ventricle’s passive diastolic stiffness. Autopsy 
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and biopsy studies of patients with severe pressure overload in the form of 
chronic hypertension or aortic stenosis frequently show changes in collagen 
architecture. This is manifest as significant increases in the percentage of 
fibrosis occupying the myocardium (77, 78). Therefore, ventricular 
hypertrophy is as a consequence of both myocyte growth and increase in extra 
cellular matrix. This is initially compensatory but then leads to deleterious 
effects physiologically. 
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1.3 ECHOCARDIOGRAM AND LEFT VENTRICULAR 
HYPERTROPHY 
 
1.3.1 LV Mass Measurements 
In clinical practice, LV chamber dimensions are used to derive measures of 
LV systolic function, whereas in epidemiological studies and treatment trials, 
one of the largest applications of echocardiography has been the estimation of 
LV mass in populations and its change with antihypertensive therapy. All LV 
mass algorithms, whether using M-mode, 2D, or 3D echocardiographic 
measurements are based on subtraction of the LV cavity volume from the 
volume enclosed by the LV epicardium (outer surface) to obtain LV muscle 
volume. This volume is then converted to mass by multiplying by myocardial 
density. Following this principle, several methodologies have been used to 
calculate left ventricular mass and to define hypertrophy. Each method has its 
own flaws and strengths at each step, all of which results in a wide range of 
values.  
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!
Critical Steps in Determining and Interpreting Left Ventricular 
Hypertrophy using Echocardiography 
1. Imaging – Mode and Acquisition 
2. Estimating Left Ventricular Volume 
3. Defining Border Limits  
4. Calculating Mass – LV Mass Formulas 
5. Indexing for Body Size 
6. Determining Cut-off Points 
     a. Using a reference sample (normality/statistical criteria) 
     b. Using prognostic data (driven by clinical endpoint) 
7. Evaluation of Left Ventricular Structure !
 
The most significant echocardiographic limitation is related to inadequate 
image quality. Population-based studies using standard trans-thoracic 
echocardiography are not able to obtain complete images in almost a quarter 
of screened patients mainly due to inadequate acoustic windows and poor 
endocardial definition (79). 
 
1.3.2 Imaging Mode and Acquisition 
LV mass can be calculated using M-mode and 2D imaging, although M-mode 
imaging allows better endocardial border definition as it has greater resolution 
due to higher frame-rate (80). To date, most LV mass calculations in studies 
and guidelines have been made using 2D targeted M-mode measurements.  
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1.3.3 Defining Endocardial Borders 
Ultrasound signals are enhanced where surfaces change density and this 
allows definition of edges. The exclusion or inclusion of these signals from 
myocardial interfaces can cause significant discrepancies in the overall 
measurements. Initial M-mode standards recommended measurement from 
the leading edge (nearest the echo probe) to trailing edge (edge further from 
echo probe) in the septum and from leading edge to leading edge of the 
posterior wall. The Penn Convention Criteria excludes echos from the wall 
boundary edges. This approach underestimated LV mass when compared to 
the most accepted border definition criteria of the American and European 
Societies of Echocardiography criteria, which measure leading edge to 
leading edge (Figure 1.1) (79). 
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Figure 1.1 Echocardiographic Endocardial Definition of Left Ventricular 
Mass Formulas. (Image from Foppa et al 2005) (79) 
The Standard convention used the leading edge to trailing edge in the 
septum and leading edge to leading edge in the posterior wall. 
The Penn formula excludes all echoes from all walls and uses the trailing 
edge to leading edge in the septum and posterior walls 
The ASE criteria use leading edge to leading edge in all walls 
 
ASE – American Society of Echocardiography 
LVDd – Left Ventricular Dimensions in diastole 
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1.3.4 Calculating LV Mass – LV Mass Formulas 
Formulas to estimate LV mass are variations on the same mathematical 
principle. Where LVIDD, PWTD and IVSD are Left Ventricular Internal 
Diameter in Diastole, Posterior Wall Thickness in Diastole and Septal Wall 
Thickness in Diastole, respectively. Original calculation from Troy were the 
first to be recommended (81): 
TROY FORMULA: 
LV Mass = 1.05 ((LVIDD + PWTD + IVSD)3 – (LVIDD)3)g 
DEVEREUX FORMULA 1: 
Devereux used a different modified equation based on narcolepsy findings of 
34 patients, using the Penn Conversion as the border definition criteria (82): 
LV Mass (Penn) = 1.04 ((LVIDD + PWTD + IVSD)3 – (LVIDD)3) – 13.6g. 
DEVEREUX FORMULA 2: 
Devereux then proposed a new adjusted equation, validated on necropsy 
findings of 52 individuals, using the ASE convention on border definition 
(83): 
LV Mass (ASE) = 0.8(1.04 ((LVIDD + PWTD + IVSD)3–(LVIDD)3)) +0.6g 
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The American and European Societies of Echocardiography both recommend 
Devereux Formula 2 for estimation of LV mass as it is validated by necropsy 
(r = 0.90, P < 0.001) (17). 
This is the reason I have used this formula to calculate LV mass in this study 
and I have excluded patients with LV systolic dysfunction as this formula is 
appropriate for evaluating patients without major distortions of LV geometry 
(e.g. patients with previous myocardial infarctions and poor LV systolic 
function).  
1.3.5 Indexing for the Patients Body Size 
Both body size and body habitus are associated with LV dimensions and 
mass. Several indices for body size correlation have been proposed such as 
height, body surface area and body mass index. Different criteria for body 
size adjustment and their cut off values result in different prevalence of LVH 
in population studies. The body surface area correction reduces variability due 
to body size and gender, but this index underestimates LV mass in overweight 
and obese individuals (84, 85). The ability to detect LV hypertrophy related to 
obesity is enhanced by indexing LV mass for the power of its growth relation 
with height (height 2.7). This is derived from regression models in normal 
samples from De Simone and appears to offer the most accurate estimation of 
LV hypertrophy particularly in obese individuals (86). Other studies have 
found LVH indexed to Height 2.7 to be a better predictor of cardiovascular 
events than LVH indexed using body surface area (87-89). 
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1.3.6 Determining Reference Values for LVH 
LV mass, as with most biological variables, are in a Gaussian distribution.  
The determination of abnormal values is a source of controversy that includes 
differences in LVH formulas, sex, ethnicity, body size etc as explained 
previously. In this study LVH was defined as LV mass index greater than 
110g/m2 for females and 134g/m2 for males using standard criteria (85). LV 
mass indexed to Height2.7 greater than 50g/m2.7 in males and greater than 
47g/m2.7 in females was defined as LVH. These represent the upper limits of 
the normal sex-specific 95% confidence intervals (CIs) of a reference 
population of 137 men and 91 women aged 18 to 73 years (84, 86). 
 
1.3.7 Geometric Patterns of LVH 
Calculation of Relative Wall Thickness (RWT) by the formula: 
2 X PWTD/ 
LVIDD 
permits categorization of an increase in LV mass as either concentric 
(RWT>0.45) or eccentric (RWT<0.45) hypertrophy and allows identification 
of concentric remodeling (normal LV mass with increased RWT). 
 
 38 
Numerous studies have established that the left ventricle adapts to stress, such 
as hypertension, by developing a variety of geometric patterns of which four 
have been defined (Figure 1.2):  
 
1. Normal geometry (Normal LVMI & RWT) 
2. Concentric remodeling (Normal LVMI & Increased RWT) 
3. Eccentric LVH (Increased LVMI & Normal RWT) 
4. Concentric LVH (Increased LVMI & RWT).  
 
 The traditional hypertensive pattern of concentric LVH has been observed in 
only a minority (6%-24%) of asymptomatic hypertensive patients in most 
studies (90-95). In these studies a larger proportion of hypertensive patients 
had, eccentric LVH, concentric remodeling, or normal LV geometry than 
concentric LVH. In a prospectively planned echocardiographic sub-study 
involving 960 patients of the Losartan Intervention For Endpoint reduction in 
Hypertension (LIFE) study, 45.6% of patients had Eccentric Hypertrophy 
compared to 23.9% who had Concentric Hypertrophy, 19.1% who had 
normal geometry and 10.5% who had Concentric Remodeling (91). The 
average age of this population was 65 years with just over half being male. 
 
In one of the largest studies to date investigating the prevalence of LVH in the 
general population, Milani and colleagues assessed echocardiograms from 
35,602 participants from a clinical echocardiographic database in New 
Orleans (96). These participants had no evidence of aortic stenosis and had a 
normal left ventricular ejection fraction. The average age of this population 
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was 60 years and 47% were male. There was no information in the paper 
about the prevalence of hypertension in this group. The most common pattern 
was of normal geometry (54%) followed by concentric remodeling (35%), 
concentric hypertrophy (6%) and eccentric hypertrophy (5%).  
 
 
Krumholz and colleagues studied the echocardiographic pattern of LV 
remodeling in 3,216 participants of the Framingham population who had 
adequate quality echocardiograms and found different relative prevalences to 
that of Milani, despite both populations being similar (97). The average age of 
the Framingham cohort was 55years for male and 57 years for female subjects 
with 43.5% of the population being male. In this population 76% of males and 
72% of females had normal geometry followed by 8% of males and 12% of 
females having eccentric hypertrophy. There were 8% of males and females 
with concentric remodeling and concentric hypertrophy. The main difference 
in the two groups was that there was more concentric remodeling in Milanis 
paper and more normal geometry in the Framingham population. The 
prevalence of concentric hypertrophy and eccentric hypertrophy were similar 
in both groups of between 5% and 8%. Of this cohort; 23% of females and 
18% of males were taking antihypertensive medication.  
 
Therefore, in a general population, the majority of people have normal 
geometry and the three patterns of abnormal geometry are equally distributed.
 40 
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In a large cohort study of 988 patients undergoing coronary angiography for 
investigation of coronary artery disease, there was a very large prevalence of 
concentric hypertrophy in those with (25%) and without (30%) coronary 
artery disease (98). Of those without coronary artery disease 25% had normal 
geometry, 33% had concentric remodeling and 17% had eccentric 
hypertrophy. In patients with confirmed coronary artery disease (at least one 
artery with >70% narrowing) 31% had normal geometry, 19% had 
concentric remodeling and 20% had eccentric hypertrophy. The average 
age of this population was 55 years with 36% of those without coronary artery 
disease and 55% with coronary artery disease being male. There was 83% 
prevalence of hypertension in both groups.  
 
In a study of 165 patients with untreated hypertension, abnormal LV 
geometry was found in 48%. This comprised 13% with concentric 
remodeling, 27% with eccentric LVH, and 8% with concentric LVH (90). 
In another series of 271 untreated hypertensive patients, abnormal LV 
geometry was found in 35%, including 20% with concentric remodeling, 9% 
with eccentric LVH, and 6% with concentric LVH (94). Therefore, in a 
population of patients with hypertension, abnormal geometry is very 
prevalent, generally more than 30% of patients. The distribution of geometry 
is heterogeneous in this group in the different studies. 
 
In a case control study involving patients with first diagnosed stroke and age, 
sex and ethnic race matched controls; Di Tullio and colleagues examined the 
prevalence of abnormal LV geometry and prognosis (99). Stroke patients had 
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a significantly higher proportion of concentric hypertrophy (13% versus 
6%) and eccentric hypertrophy (33% versus 20%) than controls. Normal LV 
pattern was significantly more frequent in controls compared to stroke 
patients (65% versus 43%). There was no statistical difference in amount of 
concentric remodeling between the groups, with 11% in stroke patients and 
9% in controls.  Patients who have suffered ischaemic strokes have similar 
prevalence of LVH to that of patients with hypertension. 
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1.4 BLOOD PRESSURE AND LEFT VENTRICULAR 
HYPERTROPHY 
There is an important misconception that patients with LVH are always 
hypertensive. In Framingham, LVH occurred in 28% of women over 60 years 
with a systolic blood pressure within the normal range (BP 125-139mmHg) 
(10). The Strong Heart study looked at the relationship of 
echocardiographically determined LV mass to demographic variables, blood 
pressure and cardiac function in 1,935 Native American Indians. This large 
study showed that half of the variability in LV mass was unexplained. Of the 
proportion that could be explained, there were six independent predictors of 
LV mass; and systolic blood pressure was only the third most important 
(100). In a study of diabetic patients in Ninewells Hospital, Dundee, blood 
pressure could not accurately identify those patients that had LVH. Twenty 
Six percent (26%) of diabetics who had normotensive office blood pressures, 
on or off antihypertensive medication (SBP<140mmHg) had 
echocardiographic LVH (101). In 7,924 adults in the second National Health 
and Nutrition Examination Survey (NHANES II) population there was 
evidence of LVH in 6.4% of those without hypertension (8). 
The lack of correlation between blood pressure and LVH seen in these studies 
is likely to be mirrored by my population of PAD patients in this study.  The 
important point here is that the prevailing level of blood pressure is in general, 
a poor predictor of the presence of LVH and probably an even poorer 
predictor in PAD patients. This will be investigated in my study. 
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The existence of ‘normotensive’ LVH does illustrate that all cut-offs are 
artificial to some extent and that all parameters are really in a continuous 
distribution. In clinical practice, so-called "normotensive" patients with LVH 
exist and they deserve better control of their risk factors. In routine clinical 
practice, doctors act more in response to cut-offs and targets than respond to 
continuous distributions; this is understandable but potentially puts patients at 
danger if risk factors are not modified. Another related issue is that 
normotensive LVH patients are probably a heterogeneous group, which 
includes normotensive LVH individuals with BPs in the upper normal range 
and whose "normal BPs" should perhaps be reclassified as high. There are also 
groups of patients with normal clinic blood pressure but hypertensive out of 
the office setting, or those patients whose blood pressure does not follow the 
circadian rhythm and drop overnight. There are a proportion of hypertensive 
patients whose LV masses have not regressed into the normal range but whose 
BPs have fallen into the normal range, who also may benefit from more 
intensive risk factor modification. Indeed, in a study of 2,051 people in a 
general Italian population aged 25 to 74years, 20% of successfully treated 
hypertensive individuals using 24 hour Blood Pressure monitoring and 5% of 
normotensive individuals had LVH (102). In this large population study LVH 
was more common in patients with poorly controlled hypertension (33%) 
compared to those that had good blood pressure control (20%) suggesting 
regression of LVH with good anti-hypertensive treatment.  
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What is clear is that hypertension is a risk factor for LVH but not everyone 
with hypertension develops LVH and conversely not everyone with LVH has 
hypertension. There is a significant population with normal blood pressure but 
have LVH evident and are at risk of complications from this. This study will 
shed light on the association of blood pressure and LVH in a population of 
patients with newly diagnosed PAD.  
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1.5 PROGNOSIS AND LEFT VENTRICULAR 
HYPERTROPHY 
 
It is well established that LVH determined by ECG, Echocardiography or 
MRI is a powerful risk factor for cardiovascular morbidity and mortality with 
relative risks of between 1.5 to 4.0 for cardiovascular morbidity and between 
1.5 and 8.0 for all-cause mortality (8, 9, 11-13, 15, 88, 89, 91, 95, 97, 99, 103-
121). Starting as an adaptive mechanism to compensate for increased cardiac 
workload, LVH can contribute to increased rates of cardiovascular events 
through its deleterious effects on ventricular function, coronary circulation, 
and arrhythmogenesis. The prevalence of LVH is dictated somewhat by age, 
increasing from 6% in Framingham subjects under age 30 years to 43% in 
those aged 70 years or older, this remains true even after multivariate analysis 
(10). LVH prevalence also varies with severity of hypertension, ranging from 
less than 10% in people with normal blood pressure to >40% in patients with 
hypertension (8, 10, 33, 67, 90, 92, 100, 102, 118, 122-136). After adjustment 
for confounding factors left ventricular hypertrophy remains an important 
independent risk factor for morbidity and mortality. 
 
1.5.1 LVH and Cardiovascular Morbidity 
1.5.1.1 Electrocardiographic LVH and Morbidity 
The difficulty interpreting studies using ECG LVH criteria is that they vary 
between studies and include the Perugia score, the Minnesota Code, voltage 
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criteria (Sokolow-Lyon index, Cornell voltage, Romhilt-Estes point score) 
and other study-specific criteria using QRS voltage, ST segment, and T-wave 
changes. Studies using ECG criteria reveal that LVH is associated with a 1.6- 
to 4.0-fold higher risk of future cardiovascular morbid events (114, 137-146). 
The populations in these studies were heterogeneous and included those with 
acute myocardial infarction, hypertension, elderly subjects (over the age of 70 
years), and the Framingham population. Most studies had a predominantly 
male population. LVH was more prevalent in male compared to female 
patients. The prevalence of ECG LVH ranged from 6% to 35% with the 
lowest prevalence in the Framingham group and the highest in male patients 
in an outpatient hypertension clinic using the Sokolow-Lyon criteria (139). 
Follow-up times in these studies ranged from 1 to 10 years. In most of these 
studies LVH was associated with increased cardiovascular morbidity in the 
form of myocardial infarction, angina, stroke, transient ischaemic attack, 
symptomatic aorto-illiac occlusive disease, peripheral thromboembolism and 
congestive cardiac failure even after multivariate analysis. Echocardiography 
is more sensitive and specific for diagnosing LVH and so I have presented 
only limited data on ECG diagnosis of LVH and concentrated on presenting 
data in the next section on Echo LVH. 
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1.5.1.2 Echocardiographic LVH and Morbidity 
The prevalence of LVH using echocardiographic criteria varies in all studies 
due to differing LVH criteria and, similar to those studies using ECG criteria, 
different heterogeneous population studied; but ranges from 10% to over 70% 
(7, 11, 12, 16, 89, 91-93, 95, 97, 99, 103, 104, 106, 107, 110, 115, 116, 122, 
124, 126, 147-152). The majority of these studies were on Caucasian 
populations with hypertension or recent history of myocardial infarction. Other 
groups studied were dialysis patients, elderly patients, Afro-American 
populations, the Framingham population, inner city hospital populations, the 
LIFE Study population and patients presenting with first stroke.  All these 
studies demonstrate that LVH is exceedingly common in different populations 
of patients with cardiovascular risk factors and disease.  
 
These studies also reveal that LVH is consistently and powerfully associated 
with cardiovascular morbidity with a 1.5 to 3.5 fold higher risk of future 
cardiovascular morbid events even after adjustment for cardiovascular risk 
factors such as age, sex, cardiovascular disease, cholesterol, smoking, 
hypertension, diabetes, BMI and LV systolic function. End points defining 
cardiovascular disease varied among studies but included cerebrovascular 
thrombotic events (stroke or TIA), myocardial infarction, heart failure and 
angina. LV mass was indexed to body surface area or height with different 
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cutoff values for LVMI in each study. Follow-up periods in these studies 
ranged from 1 to 10 years. 
Even in a relatively low risk group of individuals LVH is a powerful 
independent prognosticator for future cardiovascular morbidity. In one of the 
largest studies to date looking at the prognostic implications of LVH, Levy and 
colleagues demonstrated a relative risk of cardiovascular disease (in the form 
of coronary heart disease, congestive heart failure, stroke or TIA and 
intermittent claudication) of 1.49 for each increment of 50g per metre in LV 
mass corrected for height in men and a relative risk of 1.57 in women (11). 
These relative risks were based on multivariate analyses correcting for age, 
diastolic blood pressure, pulse pressure, antihypertensive treatment, 
cholesterol, smoking, diabetes, BMI and ECG evidence of LVH. This was 
during a 4-year follow-up of 3,220 subjects enrolled in the Framingham Heart 
Study who were free of clinically apparent cardiovascular disease and had 
echocardiographically determined LV mass. 43.5% of this population were 
male and the average age was 54.5 years for males and 56.9 years for females. 
15.5% of males and 21% of females in this cohort had echocardiographically 
determined LVH. So, even in a low risk general population LVH is seen to be 
very prevalent and an important pointer to future cardiovascular events. In my 
PAD population, I expect the prevalence of LVH to be higher and therefore a 
very important and potentially reversible prognostic marker. 
Another study with a relatively low risk population demonstrated a similar risk 
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of stroke in people with LVH compared to those without. The study population 
consisted of 1,792 participants of the Atherosclerosis Risk in Communities 
(ARIC) study which was a prospective, population based investigation in the 
United States (147). The unadjusted relative risk of ischaemic stroke was 1.36 
for every 10g/m2.7 increment. In a multivariate analysis adjusting for age, sex, 
hypertension, systolic blood pressure, smoking diabetes mellitus, cholesterol, 
BMI, coronary artery disease, congestive heart failure, left ventricular ejection 
fraction and left atrial size the relative risk was 1.17. The average age of this 
population was 58.8 years with 35.7% men. In this mainly African American 
cohort with a median follow up of 8.8 years there was a high prevalence of 
LVH in those who developed a stroke (62.2%) compared to those with no 
stroke (38.6%) (147). It is important to point out that in this population based 
study; LVH was a significant independent predictor of ischaemic stroke, even 
taking into account traditional risk factors. 
In a population based case-control study comparing 394 mostly Hispanic 
patients with first ischaemic stroke with 413 age, sex and ethnic race matched, 
stroke free controls, LVH was associated with a 2.5 fold increase in stroke risk 
after adjustment for other risk factors (99). Concentric LVH carried the 
greatest stroke risk with a relative risk of 3.5. The average age of this 
population was 68 years with 46% males, 17.2% white, 28.2% black and 
54.6% Hispanic. Few studies are available on a mixed race population, 
especially representing the Hispanic community. This study demonstrated that 
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LVH was independently associated with the risk of stroke in all ethnic groups 
with an adjusted odds ratio of 4.6 for whites, 2.1 for blacks and 2.3 for 
Hispanic individuals.  
The mechanism of ischaemic stroke is not clear. LVH may cause 
cerebrovascular events due to its relation to left atrial enlargement and atrial 
fibrillation; which are known risk factors for stroke and TIA (153-156). . This 
will be discussed in a future section of this thesis. 
 
 
1.5.1.3 Summary of LVH and Cardiovascular Morbidity 
There is a strong and reliable relationship between the presence of either ECG 
or Echocardiographic LVH and cardiovascular morbidity in the form of angina, 
myocardial infarction, stroke, transient ischaemic attacks, peripheral embolism, 
symptomatic aorto-iliac disease and heart failure. The overall weighted 
adjusted relative risk of cardiovascular morbidity in ECG and 
echocardiographic LVH studies combined is approximately 2.0.  This is true 
for all ethnic races studied. 
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1.5.2 LVH AND MORTALITY 
1.5.2.1 Electrocardiographic LVH and Mortality 
ECG is the first line method for assessing for LVH due to its availability, cost 
and ease of use. In a recent review of 26 studies investigating the utility of 
ECG LVH as a prognostic marker for mortality the prevalence of ECG LVH 
varied from 0.6% to 40%, with an average prevalence of 18% in the pooled 
population (157). This extensive review included 40,444 individuals with 
hypertension and LVH was defined by 15 different criteria, demonstrating the 
heterogeneous nature of defining ECG LVH. Vakili published a review of ten 
studies evaluating a total of 38,262 individuals from diverse populations with 
cardiovascular risk factors or disease, and demonstrated the risk of all-cause 
mortality was 1.5- to 6.8 fold higher among those with ECG evidence of LVH 
at baseline (12). Mean age was greater than 48 years with the prevalence of 
LVH ranging from 1%, in patients undergoing angiography to 44% in patients 
with hypertension. The ECG LVH criteria varied between studies and included 
the Romhilt-Estes, Minnesota Code, and other study-specific criteria using 
QRS voltage, ST segment, and T-wave changes. Mean follow-ups were 
between 4 years to 10 years. The highest RR (6.8) was observed among 
patients with LVH seen in the emergency department with angina; however, 
this figure was not adjusted for other risk factors. In the two studies reporting 
outcomes by sex, LVH conferred a higher risk in women in one study (141) 
and a slightly lower risk in another (139), compared with men (2.4 vs 2.0 and 
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2.1 vs 2.2, respectively). ECG evidence of LVH is a useful and powerful test 
for risk stratification regardless of the patient population or ECG criteria used. 
Each ECG criteria has its own sensitivity and specificity, which is inferior to 
that of echocardiography. These are the reasons I have concentrated on 
echocardiographically assessed LVH in my study. 
 
1.5.2.2 Echocardiographic LVH and Mortality 
The prevalence of Echocardiographically determined LVH in studies looking 
at mortality, as with morbidity, varies substantially depending on the criteria 
used and the population studied. In a review of 30 studies, including 37,700 
untreated and treated hypertensive patients, prevalence varies from 10% up to 
77% (158). Eccentric LVH was more frequent than concentric LVH (20.3% 
versus 14.8% respectively). As with ECG diagnosis of LVH, the studies using 
echocardiography are also heterogeneous with 23 different criteria being used. 
This emphasizes the fact that there is weak consensus about the most accurate 
method and values used to assess the presence of LVH and different formulas 
used in different populations of subjects. This limits somewhat the accurate 
assessment of risk of LVH in defined populations. Nevertheless, there is no 
doubt that LVH is prevalent is prognostically devastating.  
In a review of seven heterogeneous prospective studies evaluating a total of 
5,478 patients, the relative risk for all-cause mortality associated with baseline 
LVH ranged from 1.0 to 8.0 (12). These studies included low risk patients such 
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as the Framingham population and high-risk populations, such as those with 
end stage renal disease, diabetes, ischaemic heart disease and hypertension. 
The prevalence of LVH ranged from 16% among Framingham men to 74% in 
patients with end-stage renal disease (11, 159). Follow-up ranged from 2 to 12 
years, mean age was greater than 50 years and the majority of patients were 
men. 
LVM indexed for body surface area was used in most studies to define LVH; 
however, one study used LVM indexed for height and another used a 
combination of wall thickness and ejection fraction (11).  
All studies except one, reported outcomes after adjustment for baseline risk 
characteristics. Studies that reported end points by sex found a higher RR in 
women (2.0 to 4.3) with baseline LVH than their male counterparts (1.5 to 
2.0). The one study that did not find any increased risk associated with baseline 
LVH was conducted in patients with end-stage renal disease, 79% of whom 
had CAD, peripheral arterial disease, or arrhythmia and had an overall median 
survival of 50 months (159). This is likely to be because this population has a 
very poor prognosis anyway because of severe concomitant cardiovascular 
disease and the presence of LVH in this group has minimal extra effect.  
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1.5.2.3 Summary of LVH and Mortality 
There is a consistently powerful relationship between the presence of either 
ECG or Echocardiographic LVH and all-cause mortality. Excluding the study 
of high risk dialysis patients (159), the overall weighted adjusted RR of all-
cause mortality associated with LVH, in ECG and echocardiographic LVH 
studies combined, was 2.5 in the review by Vakili and colleagues (12). The 
mean overall risk of cardiovascular morbidity, in the form of angina, MI, 
stroke, peripheral arterial disease in this study is 2.3. 
 
The overall risk of morbid or mortal events is roughly similar for ECG and 
Echo LVH but echocardiography has a better sensitivity and specificity at 
diagnosing this condition. The prevalence of baseline LVH in studies using 
echocardiography was between 16% and 74%, compared to between 1% and 
44% in studies using ECG criteria(12). In this paper they estimate that, if the 
prevalence of LVH was 20% in a population and the adjusted RR is 2.0, then 
almost 20% of cardiovascular events would be associated with LVH. 
Left ventricular hypertrophy has not been studied in patients with peripheral 
arterial disease but is likely to be far more prevalent than 20%, given its risk 
factors and therefore confer a significant risk of cardiovascular morbidity and 
mortality.  
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1.5.3 LVH GEOMETRY AND PROGNOSIS 
We have seen that LVH is prevalent in many populations, especially those 
with cardiovascular risk factors or disease and is a significant risk factor for 
morbidity and mortality. Geometric LV pattern may also be important and 
contain additional prognostic information.  
In a study of 988 consecutive patients undergoing coronary catheterization, 
the risk of all-cause mortality per 100 patient-years for patients with normal, 
concentric remodeling, eccentric and concentric LVH was 1.5%, 1.7%, 
2.8%, and 4.2% respectively, in patients without coronary disease. Mean 
follow-up was 9 years. In patients with proven coronary artery disease the risk 
was almost doubled at 2.7%, 3.6%, 5.4%, and 7.6% respectively (Figure 
1.3) (110). In this cohort, concentric LVH conferred a significantly increased 
relative risk of all cause mortality (2.21) and cardiovascular mortality (2.97). 
Eccentric LVH conferred a moderate risk of all cause mortality and 
significant risk of cardiovascular mortality (RR 1.33 and 2.87 respectively) 
(98).  
In an observational study of 280 patients with essential hypertension and no 
prior cardiac disease, the 10-year incidence of cardiovascular events and 
death was worst in patients with concentric hypertrophy (31%, 21%) 
compared to those with eccentric hypertrophy (23%, 10%), concentric 
remodeling (15%, 3%) and normal geometry (11%, 0%) (92). Verdecchia 
and colleagues demonstrated in a study of 694 hypertensive patients with 
normal LV mass (<125g/m2) the risk of cardiovascular events was 
statistically higher in the group with concentric remodeling compared to the 
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patients with normal geometry (relative risk 2.56) over a mean follow-up of 
7.7 years (116).  
 
 
Figure 1.3 Risk of All Cause Mortality in Patients with and 
without Coronary Artery Disease (CAD) in patients undergoing 
coronary catheterization. Data from Ghali et al (1998) (98) 
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Data from the Framingham Heart Study using 3,209 patients, who were ≥40 
years old and free from cardiovascular disease with adequate follow up and 
good quality echocardiogram, showed that the cardiovascular event rates in 
men and women were highest in the concentric hypertrophy group and lowest 
on the normal geometry group. This was even after adjustment for traditional 
cardiovascular risk factors (97). This study showed a relative risk of 2.1 for 
all cause mortality in men and a RR of 1.6 in women with concentric 
hypertrophy (97). This study demonstrated that subjects with concentric 
hypertrophy had the worst prognosis followed by those with eccentric 
hypertrophy, concentric remodeling and normal geometry. It is important to 
emphasize that this was in a population who were free of cardiovascular 
disease at baseline.   
 
Taken together, these studies illustrate that LV geometry stratifies risk of 
adverse outcomes and is independent of BP and other conventional risk 
factors. More recently, LV geometry was also demonstrated as a predictor of 
cardiovascular risk during antihypertensive drug therapy in the LIFE 
Echocardiography Sub-study (91). Out of the 9,193 patients in the parent 
LIFE Study, 960 subjects were prospectively assessed with annual 
echocardiographic follow-up. Among the 960 patients, analysis was 
undertaken in the 937 patients with measurable LV dimensions on the 
baseline echocardiogram. The study demonstrated at baseline that among 
hypertensive patients with ECG signs of LVH, the most common LV 
geometry was eccentric LVH (47%), followed by concentric LVH (24%), 
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normal (19%) and concentric remodelling (10%). However, LV geometry 
changed significantly during follow-up as a result of aggressive 
antihypertensive treatment. By the end of the follow-up period of 4.8 years, 
the proportions with each of these LV geometries were 30%, 5%, 63%, and 
3%, respectively (P< 0.001). Baseline LV geometry did not predict outcome 
in the LIFE substudy but in multivariate Cox regression analysis, each 
abnormal LV pattern after treatment independently predicted risk of the 
composite endpoint compared with normal LV geometry (P<0.05) (Figure 
1.4).  
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Figure 1.4 Influence of LV Geometry on Cardiovascular Risk 
after Treatment in the Losartan Intervention for Endpoint 
Reduction in Hypertension (LIFE) Echocardiography Study.  
P<0.05  
No patients with concentric remodeling at final study experienced 
myocardial infarction 
Modified from Gerdts et al 2008 (91) 
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When the individual components of the composite endpoint were considered 
separately in similar multivariate models: 
 
Concentric remodeling was associated with increased risk of 
cardiovascular death (HR 7.85) and stroke (HR 3.02), 
Eccentric hypertrophy with increased risk of cardiovascular death 
(HR 3.24) and MI (HR 2.56), and 
Concentric hypertrophy with increased risk of MI (HR 4). 
 
This analysis demonstrates that evaluation of LV geometry after treatment 
adds prognostic information to clinical evaluation and assessment of LVH in 
patients with hypertension, with concentric remodeling showing the highest 
risk of cardiovascular death. 
 
A population based case-control study with 394 patients with first ischemic 
stroke and 413 age, sex and ethnically matched controls demonstrated 
concentric hypertrophy carried the greatest stroke risk with an adjusted OR of 
3.5. This was followed by eccentric hypertrophy (OR 2.4) and concentric 
remodeling (OR 1.7) (99). This is in contrast to the LIFE substudy 
population. 
 
Analysis using 5,888 participants of the Cardiovascular Health Study (CHS), 
which is a longitudinal, multicenter cohort study of elderly men and women 
(>65 years old) found that eccentric and concentric LVH increased the risk of 
heart failure (Adjusted HR 2.95 and 3.32 respectively) and coronary heart 
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disease (Adjusted HR 2.02 and 1.61 respectively) (109). No LV geometric 
pattern increased the risk of stroke in this elderly general population.  
 
Additional data will be needed to determine whether the adverse implications 
of specific LV geometric patterns are consistent across populations and 
remain significant in analyses adjusting for co-variates. Overall, it appears 
that concentric hypertrophy consistently confers the worst prognosis in most 
of the studies with information on geometric patterns.  In the LIFE substudy 
by Gerdts and colleagues, concentric remodeling conferred the worst 
prognosis in terms of cardiovascular death (91). A possible explanation for 
this is that this abnormal geometric pattern is more difficult to reverse with 
pharmacological therapy, thereby increasing the risk. In comparison, 
concentric hypertrophy regresses more easily with anti-hypertensive therapy 
and therefore may improve prognosis. I will discuss this in more detail in the 
later section on LVH regression. 
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1.5.4 PROGNOSIS AND LVH SUMMARY 
The relationship between the presence of either ECG or Echocardiographic 
LVH and subsequent cardiovascular and all-cause mortality is impressively 
strong. This is consistent for all populations studied. 
 
Women with LVH appear to be at equal, if not higher risk, of adverse 
outcomes compared to their male counterparts. The average weight adjusted 
RR of cardiovascular morbidity is 2.0 for females versus 2.4 for males. With a 
RR of all-cause mortality being 2.3 for females versus 1.9 for males.  
 
On a population basis, the clinical significance of the association between 
LVH and cardiovascular events depends, in part, on the prevalence of LVH. 
The prevalence of baseline LVH is higher in studies using anatomically 
validated echocardiographic methods than in studies using 
electrocardiographic criteria (16%-74% vs 1%-44%, respectively). This 
suggests that the population burden of cardiovascular events associated with 
LVH is extremely considerable. For instance, with a population prevalence of 
LVH of 20% and an adjusted relative risk of 2.0, almost 20% of 
cardiovascular events would be associated with LVH (12). If LVH is more 
prevalent than 20% in PAD patients then the amount of cardiovascular events 
is likely to be even higher in this group. 
 
One of the most comprehensive studies looking at adverse cardiovascular 
outcomes was that of Liao et al (1995). In addition to standard adjusted risk 
calculations, LVH was shown to have an even worse outcome (RR 2.4) when 
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compared to multivessel coronary artery disease (RR 2.0) and reduced 
ejection fraction (RR 1.6) (7). All these data suggested that LVH is likely to 
be far more prevalent in PAD patients and the morbidity and mortality burden 
of LVH is expected to be considerable. 
 
1.5.5 CONSEQUENCES OF LVH 
It has been consistently shown that LVH is strongly associated with the risk 
of cardiovascular morbidity, in the form of stroke, MI, heart failure, 
arrhythmia and angina. It is also strongly associated with all cause and 
cardiovascular mortality. It starts off as a compensatory mechanism and then 
becomes a powerful and independent risk factor for morbidity and mortality. 
In this section we will discuss the possible physiological reasons for these 
consequences. 
1.5.5.1 LVH, Atrial Fibrillation and Stroke 
The mechanism of ischaemic stroke is not clear but LVH may predispose 
individuals due to its relation to left atrial enlargement. Left atrial dilatation is 
a known risk factor for thromoembolism (153-156). A separate mechanism is 
that both left atrial dilatation and LVH are risk factors for atrial fibrillation 
(AF). Atrial fibrillation is the most common arrhythmia in the general 
population and its prevalence increases with age (160-162).  AF, itself, is a 
strong risk factor for ischaemic stoke, primarily because it causes left atrial 
appendage thrombus formation (154, 155, 163-167). The mechanisms 
underlying the increased thrombogenic risk of AF are complex and remain 
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only partially elucidated. In the Framingham population, AF increased the 
risk of stroke by almost five fold (168). Suggested mechanisms of the 
increased stroke risk include stasis, procoaguable state with platelet and 
clotting factor abnormalities and endothelial dysfunction and inflammation 
(164). Abnormalities in the Renin-Angiotensin-Aldosterone-System (RAAS) 
are important in numerous cardiovascular diseases. Atrial tissue has the 
ability to produce these hormones, primarily Angiotensin II, which is up 
regulated in AF (169, 170). Angiotensin II is proinflammatory, pro-apoptotic 
and pro-thrombotic. Modulation of the RAAS with either ACE-inhibitors, 
Angiotensin Receptor blockers or Aldosteone has been proven to be 
prognostically beneficial in a number of diseases including hypertension, 
LVH and heart failure. Importantly, one can reduce the incidence of atrial 
fibrillation and decrease left atrial size by treating hypertension with 
commonly prescribed medication such as angiotensin converting enzyme 
inhibitors (ACE-I) and angiotensin receptor blockers (ARB) (166, 167).  
Various substudies of the LIFE study have demonstrated a strong relationship 
between LVH and left atrial size and new onset AF. In 941 participants of the 
LIFE echo substudy (mean age 66 years), left atrial diameter was measured at 
baseline (171). Enlarged left atrial diameter was present in 56% of women 
and 38% of men and was strongly associated with LVH (OR 2.46) and AF 
(7.18) (171).  In logistic regression analysis, LA enlargement was related to 
LVH and in particular eccentric geometry. This is surprising, as it appears 
from previous LIFE studies that concentric hypertrophy carries the strongest 
risk for cerebrovascular events and not eccentric hypertrophy (171).  
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In various LIFE substudies the use of the angiotensin receptor blocker 
Losartan significantly reduces the incidence of AF by 33% and reduced stroke 
by an impressive 55% (163, 167, 171-174). Losartan reduced left atrial 
diameter by 19mm compared to just 6mm in the Atenolol arm (174). This was 
despite similar reductions in blood pressure between the two treatment groups 
(Atenolol versus Losartan). Thus, RAAS modulation has beneficial effects on 
both atrial fibrillation and stroke reduction in patients with LVH, perhaps by 
its beneficial effect on LA size. 
 
1.5.5.2 LVH, Coronary Flow Reserve and Ventricular 
Arrhythmias 
A study from the Framingham population demonstrated that LVH was 
associated with a relative risk of sudden cardiac death of 1.53 over a 14-year 
follow-up period (148). Importantly, regression of LVH in the LIFE study, 
during a mean follow-up period of 4.8 years was associated with a significant 
reduction in sudden cardiac death (HR 0.7) (175). Sudden cardiac death is 
likely related to increased ventricular arrhythmias in LVH patients. The 
possible mechanisms by which LVH causes ventricular arrhythmia are not 
well understood and are numerous. Some mechanisms may be that LVH 
prolongs the action potential in cardiac myocytes and this predisposes them to 
early afterdopolarisations and increased triggered activity (176, 177). It also 
increases refractoriness within the LV and both these mechanisms have been 
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associated with increased risk of polymorphic ventricular tachycardia and 
ventricular fibrillation (176-180).  
A hallmark of severe chronic LVH is fibrosis and collagen deposition (181-
183). Fibrosis and collagen deposition is akin to scar, which is a potent risk 
factor for ventricular arrhythmia (184). LVH reduces coronary flow reserve 
and increases myocardial oxygen requirements (185, 186). Coronary flow 
reserve is a measure of the ability of the coronary vasculature to increase its 
blood flow to compensate for states of relative ischaemia. Coronary reserve 
has been defined as the ratio of coronary resistance under control conditions 
(rest) and of coronary resistance after maximal coronary vasodilatation (using 
vasodilatory drugs in the cardiac laboratory, such as dipyridamole). This 
imbalance may predispose to cardiac ischaemia, arrhythmia and sudden death 
(187-189). Structural and functional alterations of the coronary circulation 
have been reported in LVH. In people with LVH there is a lower ratio of 
subendocardial capillaries to LV mass and therefore when vascular growth 
does not match myocyte growth there is a reduction in coronary flow reserve. 
This picture is worsened if there is medial hypertrophy of the blood vessel 
wall giving rise to luminal narrowing and a further reduction in oxygen 
supply. The reduction in coronary flow reserve in hypertrophic hearts is 
caused by both a concomitant increase in resting myocardial blood flow, due 
to higher work load and oxygen consumption, and a reduction in hyperaemic 
response to endothelial dependant and independent stressors(190-193). 
Increased myocardial and extravascular compressive forces contribute 
mechanically to myocardial blood flow reduction in LVH. The 
subendocardium is underperfused during systole and it must therefore 
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compensate during diastole. Elevated end diastolic pressure in LVH can 
reduce subendocardial perfusion, particularly during physical or 
pharmacological stress, causing signs and symptoms of ischemia in the 
absence of significant epicardial coronary artery lesions (192). Moreover, the 
risk of ischemia is higher in dilated hearts (193).  
Impaired coronary flow reserve is associated with both abnormal left 
ventricular relaxation and increased left ventricular filling pressure (194). 
Coronary flow reserve is negatively associated with LV mass (194). LVH and 
its effect on cardiac microcirculation and deleterious effect on the interstitium 
with increase in fibrosis can initiate and maintain a reduction in myocardial 
flow reserve. This is turn, can result in, not only depression of systolic 
function but also impairment of LV dispensability and increase in myocardial 
filling pressures (190, 191, 194, 195). In a substudy of The Losartan 
Intervention for Endpoint Reduction in Hypertension (LIFE) study, LVH was 
associated with impaired LV diastolic filling in a multiple regression model 
(195). A reduction in coronary flow reserve in patients with LVH initiates a 
process of reduced microvascular perfusion paralleling increased metabolic 
demand secondary to increased LV mass and pressure overload. The 
reduction in microvascular perfusion is also further reduced by the increased 
LV filling pressure and delay in LV relaxation found in patients with LVH 
(196). This is independent of levels of blood pressure. The beta-blocker, 
Nebivolol, improves LV filling pressure as well as coronary flow reserve 
(196).  
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There may also be asymptomatic coronary artery disease and narrowing in 
patients with LVH as they have similar risk factors. This will create more 
ischaemia and risk of arrhythmias and sudden death.  
 
In a recent study of 317 patients with ischaemic cardiomyopathy (mean age 
65 years) and implantable cardioverter defibrillators (ICD), ECG evidence of 
LVH was the only significant predictor of VT and VF in univariate analysis 
(105). In a multivariate analysis model it was a significant predictor of 
arrhythmia and death in this cohort. The unique advantage of this study is that 
they were able to detect arrhythmia easily due to the fact that the patients had 
an ICD and could therefore detect all significant arrhythmias. In another LIFE 
substudy of 1,326 subjects, Losartan significantly reduced the risk of sudden 
cardiac death compared to Atenolol with a HR of 0.49 (197). Losartan may 
have this beneficial effect by regressing LVH, reducing myocardial fibrosis 
and reducing cardiac arrhythmias.  
 
In summary, LVH leads to worse outcome, in terms of morbidity and 
mortality, secondary to reduced coronary flow reserve, increased LV filling 
pressure, reduced systolic and diastolic LV function and increased risk of 
myocardial infarction, stroke, atrial fibrillation, ventricular arrhythmias and 
heart failure. Numerous studies, including the numerous LIFE sub-studies, 
have proven this. Importantly, regressing LVH, and especially using 
medications that target the RAAS can attenuate much of these events. 
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1.5.6 LIMITATIONS OF LVH STUDIES 
ECG and echocardiographic criteria used to define LVH in published studies 
are not uniform and vary substantially. These differences have a potential 
impact on the prevalence of LVH, introducing a bias toward lower prevalence 
of LVH with more stringent ECG LVH criteria or higher LV Mass cutoff 
values for defining LVH and vice versa. Also, end points except all-cause 
mortality vary among studies. However, the risk of cardiovascular events 
associated with LVH is significantly increased irrespective of the prevalence 
of LVH or the end point used, suggesting that interstudy differences in LVH 
criteria or end point did not have a substantial effect on the overall evidence 
of a strong association between LVH and adverse outcomes. Taking all this 
into consideration, an important strength of most published studies is that they 
derived the estimates of risk in multivariate analyses that took potential 
confounding effects of conventional risk factors into account. This 
unequivocally confirms the strong association between LVH and adverse 
outcome.  
 
Given the higher sensitivity of the echocardiogram for detecting LVH and the 
adverse prognostic implications associated with LVH, it would be desirable to 
reach a consensus with regard to a uniform definition of echocardiographic 
LVH. This would allow more direct comparison of studies and make possible 
pooling of such data in the form of a true meta-analysis. The classic 
indexation of LV mass for body surface area is useful for detecting 
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hypertension-associated LVH but tends to mask that associated with obesity. 
In contrast, indexation of LV mass to body height (height2.7 ) appears to detect 
obesity-independent and obesity-related LVH equally well. 
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1.6 REGRESSION OF LEFT VENTRICUALR 
HYPERTROPHY 
 
A fundamentally important issue with regard to the clinical significance of 
LVH is the degree to which LVH regression is associated with improvement 
in prognosis. Individuals in whom ECG or echocardiographic LVH regressed 
have significantly lower rates of subsequent cardiovascular events than those 
in whom LVH persisted or developed. LVH regression reduces events by up 
to 75% (12, 112, 114, 118, 123, 129, 175, 198, 199).  Verdecchia and 
colleagues showed in a meta-analysis in 2003 that LVH regression lead to a 
significant reduction in cardiovascular events (OR 0.41)(200).  A meta-
analysis published 7 years later looking at the prognostic relevance of 
echocardiographically determined LVH regression in hypertensive patients 
confirmed that regression of LVH was associated with a significant reduction 
of cardiovascular events (118). In this rigorous analysis, only studies with 
multivariate analyses and adjusted hazard ratios, examining 
echocardiographic LVH regression and prognosis in hypertension were 
included. Five studies were identified, including a total of 3,149 patients with 
a follow-up of between 3 and 9 years. Overall, there was an adjusted HR of 
0.54 for either LVH regression or persistent normal LV geometry versus LVH 
development or persistence. This contemporary meta-analysis demonstrates 
that LVH regression is associated with a significant improvement in 
cardiovascular outcome in patients with hypertension.  
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Important insights regarding the physiology of regression of hypertrophy in 
patients with hemodynamic overload can be drawn from a number of studies 
on patients before and after Aortic valve replacement and septal myectomy 
for patients with hypertrophic obstructive cardiomyopathy (201-203). 
Normalisation of systolic load through aortic valve replacement causes a rapid 
reduction in myocyte hypertrophy and LV mass (35% reduction) within a few 
weeks after valve replacement. In this early phase there is rapid regression of 
myocyte hypertrophy but little change in collagen and matrix. During 
continued reduction of load many months to a few years after valve 
replacement, regression of interstitial fibrosis and further regression of LVH 
occurs, resulting in near-normalisation of both muscle mass and fibrous 
tissue. In these studies, the increased biomechanical loads were abruptly 
reduced by mechanical valve replacement in the absence of pharmacological 
interventions.  
 
Dahlof and colleagues performed a meta-analysis of 109 studies involving 
2357 hypertensive patients on the effects of antihypertensive treatment on 
LVH (204). In this analysis, ACE inhibitors reduced LV mass by 15%. 
Lesser reductions were achieved with diuretics (11%), ß-blockers (8%), and 
calcium-channel blockers (8.5%). Overall, LV mass was reduced by 11.9%, 
which is less than the magnitude of regression observed after valve 
replacement. 
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The lower magnitude of regression observed in pharmacological trials in 
hypertensive patients is likely related to an incomplete reduction of 
hypertension itself. Nevertheless, regression of LVH by pharmacological 
means reduces morbidity and mortality over and above reduction in blood 
pressure.  
 
 
1.6.1 REGRESSION OF LVH AND PROGNOSIS 
 
A double-blinded, randomized, parallel-group substudy of the LIFE (Losartan 
Intervention For Endpoint Reduction) study demonstrated that regression of 
electrocardiographic LVH by Cornell product and/or Sokolow-Lyon voltage 
criteria during antihypertensive therapy was associated with a lower likelihood 
of CV morbidity and mortality (129). This was independent of treatment 
modality and of reductions in BP. In contrast, persistence or development of 
electrocardiographic LVH by these criteria was associated with increased risk 
of CV morbidity and mortality. These findings support the value of 
electrocardiographic LVH criteria for assessing CV risk over time in patients 
with hypertension and suggest that antihypertensive therapy targeted at 
regression or prevention of electrocardiographic LVH by these criteria may 
improve prognosis.  
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Data from the Heart Outcomes Prevention Evaluation (HOPE) trial provided 
strong evidence supporting the hypothesis that regression of ECG-LVH 
improves prognosis (57). The combined end point of either regression of 
ECG-LVH or prevention of progression to ECG-LVH in response to a 
Ramipril-based therapy was associated with reduced risk of death, MI, stroke, 
and congestive heart failure. However, the usefulness of these findings is 
limited by the low prevalence of ECG-LVH in the HOPE trial (7.1%), the 
absence of adjustment for other clinical variables in outcome analyses, and by 
the absence of specific data addressing the value of changes in Sokolow-Lyon 
voltage for predicting outcome. 
A substudy of LIFE by Okin et al (2004) supports the importance of serial 
measurement of ECG LVH during antihypertensive treatment for risk 
stratification(129). They found that significantly lower values of both Cornell 
product and Sokolow-Lyon voltage were associated with 14.5% to 16.6% 
reductions in the incidence of major CV morbidity and mortality over 4.8 
years of follow-up, independent of primary study assignment to Losartan or 
Atenolol, baseline Framingham risk score, and of baseline and in-treatment 
levels of BP. Intriguingly, a simultaneous 1-Standard Deviation decrease in 
both Cornell product and Sokolow-Lyon voltage was associated with a 29% 
reduction in the composite end point of CV morbidity and mortality (38% 
decrease risk of CV mortality, 18.9% lower risk of MI and a 26.8% reduced 
risk of stroke). 
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The strong, independent relation between lower values of 
electrocardiographic LVH and reduced rates of CV events in this study is 
paralleled by findings from the echocardiographic substudies of LIFE, which 
provide evidence of a similarly powerful association of changing left 
ventricular mass with CV morbidity and mortality (112, 123, 129, 175, 199). 
Lower values of left ventricular mass were associated with a 22% lower rate 
of composite end points, a 38% reduction in CV mortality, a 24% reduction in 
stroke, and a 15% lower rate of MI. Lack of regression of LVH in these 
studies also portends a poorer prognosis. 
Taken together, these electrocardiographic and echocardiographic findings 
demonstrate that the strong association between serial assessments of LVH 
and CV outcomes is independent of the method used to serially assess the 
degree of hypertrophy. What is clear is that regression of LVH improves 
patients prognosis drastically and either development of LVH or lack of 
regression is an omen for a dismal prognosis. 
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1.7 LVH REGRESSION AND PHARMACOLOGY 
 
For many years, clinicians have been interested in finding the best drugs to 
regress LVH or improve other surrogate markers of hypertensive target organ 
damage (such as microproteinuria or endothelial dysfunction). One meta-
analysis which included only double-blind, randomized, controlled clinical 
studies with parallel-group design (39 trials) found that more LVH regression 
occurred with greater blood pressure reduction and a longer duration of 
therapy (205). Specifically, LVH regression occurred in 13% of patients 
treated with the ACE inhibitors, 9% treated with calcium channel blockers, 
6% treated with ß-blockers, and 7% treated with diuretics, suggesting that 
overall, the ACE inhibitors (or ARBs) are probably the best drugs for LVH 
regression. 
The LVH regression substudy from the Heart Outcomes Prevention 
Evaluation (HOPE) trial, which studied a broad range of patients with normal 
or controlled blood pressure, showed that ECG-LVH was regressed in 46.1% 
of patients treated with Ramipril compared with 38.6% of those treated with 
placebo (198). Importantly, this effect was independent of hypertension or 
blood pressure reduction. Furthermore, LVH prevention/regression using 
Ramipril resulted in a reduction of the primary outcomes (cardiovascular 
death, myocardial infarction, or stroke) and the prevention of congestive heart 
failure. This study represents one of the first trials that convincingly shows 
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that LVH regression really does matter, even in patients without hypertension. 
Unfortunately, the study depends on ECG criteria of LVH, and it is 
recognized that although the ECG is a useful screening tool for LVH, it has a 
relatively low specificity and sensitivity compared to echocardiography.  
The use of ACE inhibitors is well-established for the treatment of 
hypertension, heart failure, left ventricular systolic dysfunction, and perhaps 
for all patients with myocardial infarction, diabetic nephropathy and diabetic 
retinopathy. Data from the Perindopril Protection Against Recurrent Stroke 
Study (PROGRESS) also point toward the beneficial effects of the ACE 
inhibitor, Perindopril, in patients after stroke. Therefore, it is possible that 
ACE inhibitors may be the best drugs for regressing LVH and result in 
corresponding improvements in prognosis through their benefits in 
concomitant comorbidity, including underlying left ventricular dysfunction, 
diabetes, renal dysfunction, cerebrovascular disease.  
The pathophysiology of cardiovascular disease and in particular LVH may 
help us understand why ACE inhibitors provide therapeutic hope to the many 
patients with cardiovascular disease and LVH. The most obvious system 
influenced by ACE inhibitors is the renin-angiotensin-aldosterone system. 
Because angiotensin and aldosterone have deleterious effects on myocardial 
and vascular remodeling, the beneficial effects of these drugs may come 
through the blockade of these neurohormones, resulting in an antihypertrophic 
effect on the myocardium and an antiproliferative effect on smooth muscles. 
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Furthermore, despite blood vessels being exposed to higher pressures, the 
complications of hypertension (that is, myocardial infarction and stroke) are 
paradoxically thrombotic rather than hemorrhagic. As mentioned previously, 
abnormalities of haemostasis, platelets, and endothelial dysfunction are 
present in hypertension and LVH, contributing to a prothrombotic state.  
Hypertension and other vascular diseases are associated with endothelial 
dysfunction. ACE inhibitors have been shown to improve endothelial 
function. There is also some evidence that the ACE inhibitors may also 
improve insulin resistance. Nevertheless, unanswered questions remain. For 
example, the Afro-Caribbean ethnic groups are at particular risk of developing 
LVH, and it remains uncertain whether LVH regression in this group would 
translate into a prognostic benefit. Ethnic differences in cardiovascular disease 
are increasingly important considerations, and in the United Kingdom, blacks 
are at high risk of hypertension and hypertension-related complications such 
as stroke and renal damage, whereas south Asians are at a high risk of 
coronary artery disease. Indeed, the recent analysis from the Studies of Left 
Ventricular Dysfunction (SOLVD) investigators suggests that black patients 
with left ventricular dysfunction do not respond well to ACE inhibitors, 
especially if they have a past history of hypertension. Limited data on LVH 
regression and other hypertensive target organ damage are available in south 
Asians, although it is perceived that they respond to antihypertensive drugs 
similarly to whites.  
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In this study I set out to assess how prevalent LVH is in PAD patients and to 
elucidate its relation to blood pressure. If it is indeed prevalent then its burden 
on morbidity and mortality may potentially be significant in this group of 
patients. Targeting the RAAS may be a powerful tool to improve the outcome 
for these patients. 
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CHAPTER 2  
MATERIALS AND METHODS 
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2.1 Study Population and Sample Size Estimates 
I gained Ethical Approval from the Tayside Committee on Medical Research 
Ethics and the study was undertaken in accordance with their standards.  
Three hundred and fifty patients who were referred as outpatients for the first 
time because of PAD were consecutively recruited at Ninewells Hospital, 
Dundee, between March 2003 and June 2004. Six hundred and thirty one 
patients were approached by letter until 350 agreed to participate in the study. 
Sample size estimates were performed by Dr Simon Ogston (Senior Lecturer 
in Statistics, Department of Epidemiology, Ninewells Hospital). Sample size 
calculations are based on expecting the prevalence of LVH in PAD patients to 
be 30%. This figure is based on the prevalence of LVH in analogous 
populations to be approximately 35%. Studies from this institution 
(University of Dundee) demonstrated that 52% of angina patients, 42% of 
type 2 diabetics, 25% in a random group of stroke survivors and 25% in a 
random group of patients attending a geriatric day hospital have evidence of 
LVH (13, 14, 206). This means that a sample size of 323 PAD patients would 
be required to give a precision (standard error) of 2.5% in assessing the 
expected prevalence i.e. this would give a two sided confidence interval of 
95%. The standard error of a prevalence estimate in a population is: 
√(P(1-P)/n) 
where n=total number of subjects being studied, P= expected prevalence of an 
abnormality expressed as a decimal (e.g. if the prevalence is 30% then P=0.3). 
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i.e. if we expect the prevalence of LVH to be 30% and we study 323, then the 
standard error will be: 
√(0.3(1-0.3)/323) = √0.00065 = 0.025 
Expressed as a percentage, this gives a standard error of 2.5%. 
 
The inclusion criteria were a history of intermittent claudication and the 
presence of a low (≤0.9) ankle brachial pressure index.  The exclusion criteria 
included:  
 
(1) Patients with valvular, pericardial or congenital heart 
disease  
(2) Patients with an impaired left ventricular systolic function 
on echocardiography (EF<45%).  
(3) Patients with ABPI <0.5 
 
Subjects were approached by letter from a database detailing new referrals to 
the Vascular Laboratory in Ninewells Hospital, Dundee (Sample letter in 
Appendix). All subjects who volunteered for the study attended a single clinic 
visit in the hospital and underwent the following: routine history, clinical 
examination, electrocardiography, routine blood tests, transthoracic 
echocardiography and 24 hour ambulatory Blood Pressure monitoring.  
(Consent form and reporting form in Appendix). Hypertension on office BP 
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was taken as a BP of >140/90 mmHg as in the Joint British Societies (JB2) 
guidelines (2005).  
 
2.2 ECHOCARDIOGRAPHY 
Transthoracic echocardiography was performed by a single operator (Dr Gary 
Wright) using a Hewlett Packard Sonos 5500 (Andover, MA, USA) 
Echocardiographic machine. The scan was performed with the patient lying in 
the left lateral position at approximately 45o.  
 
2.2.1 Left ventricular hypertrophy assessment 
Patients were studied with two-dimensional guided M-mode 
echocardiography in standard views. All measurements were made according 
to the American Society of Echocardiography (ASE) recommendation at end 
diastole, taken as the onset of QRS complex. The leading edge to leading 
edge convention was used to measure interventricular septal (IVS) thickness, 
left ventricular internal diameter (LVIDD) and left ventricular posterior wall 
thickness (PWT). Measurements were made over at least 3 separate cardiac 
cycles and the average taken. Left ventricular mass (LVM) was calculated 
according to the formula of Devereux et al.  
 
0.80 (ASE left ventricular mass) +0.6 (83)  
 
 85 
and indexed to body surface area (BSA) to give a left ventricular mass index 
(LVMI). Left ventricular hypertrophy was defined as LVMI greater than 
110g/m2 in females and greater than 134 g/m2 in males. Left ventricular mass 
was also indexed to height 2.7 and LVH was defined as LVMI greater than 
47g/m2.7 in females and greater than 50g/m2.7 in males. LVMI was not 
calculated in cases in which either poor image quality or inadequate image 
alignment prevented accurate M-mode measurements from being made.  
 
Left ventricular geometry was classified as normal, concentric remodeling, 
eccentric left ventricular hypertrophy or concentric left ventricular 
hypertrophy, based on left ventricular mass and relative wall thickness 
(RWT). RWT was calculated as follows:  
 
2 x LV posterior wall thickness/ LV end diastolic dimension X 100%.  
 
A value of > 45% was defined as abnormal.  
 
• Normal LV geometry was defined as normal left ventricular mass and 
normal RWT 
• Concentric remodeling defined as normal left ventricular mass and 
increased RWT 
• Eccentric LVH defined as increased left ventricular mass and normal 
RWT  
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• Concentric LVH defined as increased left ventricular mass and 
increased RWT.  
 
2.2.2 Left ventricular systolic function assessment 
Quantitative assessment of left ventricular systolic function was made using 
the modified biplane Simpson’s method to calculate a left ventricular ejection 
fraction. Three measurements from successive cardiac cycles were made in 
the two chamber and four chamber views. 
 
 
2.3 BLOOD PRESSURE ASSESSMENT 
2.3.1 Office Blood Pressure 
Blood pressure was taken in the seated position, on the non-dominant arm 
(brachial artery) using a calibrated OMRON sphygmomanometer (Omron 
Healthcare Europe, Hoofddorp, Netherlands) after a period of 15 minutes rest 
using an appropriate size cuff. The average of 3 consecutive measurements 
was used. 
 
2.3.2 Ambulatory Blood Pressure (24 Hour) 
Ambulatory BP monitoring was performed with Meditech ABPM-04 
(Meditech Ltt, Budapest, Hungary) recorders on a day of typical activity in 
131 patients fitted to the non-dominant arm.  Those who underwent the test 
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were randomly chosen due to the availability of the machines, with a bias 
toward those patients with echocardiographic LVH. Ambulatory BP readings 
were obtained at 15 min intervals from 8 am to 10 pm (daytime period) and 
30 min intervals from 10 pm to 8 am (night time period). The following 
ambulatory BP parameters were evaluated: average daytime, average night 
time and 24 hour systolic and diastolic BP. Subjects included in the study 
analysis had recordings of good technical quality (at least 70% of valid 
readings). 
 
2.4 BLOOD SAMPLES 
Blood samples were taken from an antecubital vein and sent for analysis to 
Ninewells Hospital Biochemistry laboratory for total cholesterol, HDL 
cholesterol, serum creatinine (5ml of clotted blood). Four milliliters of whole 
blood EDTA samples were taken for near patient BNP testing using the 
Biosite® Triage BNP fluorescence immunoassay test kit (Biosite® Inc, San 
Diego, CA, USA).  
Normal ranges for blood tests: 
Test Male Range Female Range 
Creatinine 62-106µmol/L 44-80µmol/L 
Total Cholesterol <5.0 mmol/L <5.0mmol/L 
HDL Cholesterol >1.0 mmol/L >1.2 mmol/L 
BNP <100 pg/ml <100pg/ml 
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2.5 STATISTICS 
Values are quoted as means and 95% confidence intervals. A minimum of 
three measurements were used to calculate the mean for each parameter. 
Comparisons of continuous variables, such as blood pressure, between groups 
were performed using the one-way ANOVA test. The one-way ANOVA test 
is useful when the variables are not in a normal distribution and can tolerate 
data that is not in a typical bell shaped curve. Comparisons between 
categorical variables, such as presence or absence of LVH, were performed 
using the chi-square test. Multivariate forward regression analysis was 
performed to establish which variables were independently related to left 
ventricular mass. All statistical analyses were performed using SPSS for 
Windows version 13.0. A value of p<0.05 was considered to be statistically 
significant. See section 2.1 Study Population for a more in-depth explanation 
of sample size calculations and rationale. Sample size calculations were 
performed by Dr Simon Ogston (Senior Lecturer in Statistics, Department of 
Epidemiology, Ninewells Hospital). Sample size calculations are based on 
expecting the prevalence of LVH in PAD patients to be 30%. This figure is 
based on the prevalence of LVH in analogous populations to be 
approximately 35% as stated above. 
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CHAPTER 3 
RESULTS 
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The following consort diagram shows a flowchart of recruitment with six 
hundred and thirty one patients being approached resulting in three hundred 
and fifty participants in the study. Analysis was carried out in two hundred 
and twenty seven patients as LV mass was available in two hundred and forty 
one. Fourteen patients were excluded because of an LV ejection fraction of 
less that forty five percent. 
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3.1 ECHOCARDIOGRAPHIC LEFT VENTRICULAR 
HYPERTROPHY (INDEXED TO BODY SURFACE AREA) 
Patient characteristics of the 350 patients recruited are listed in Table 3.1.  M-
mode measurement of LV mass was obtainable in 241 patients (69%).  Those 
in whom M-mode LV mass could not be assessed did not differ significantly 
in any other parameters from those in whom an adequate M-mode 
measurement was obtained (Table 3.2). Out of the 241 patients with M-mode 
LV mass, 14 patients were excluded due to low ejection fraction. Of the 
remaining 227 patients with preserved LV systolic function, the proportion of 
patients with LVH was 50% (114/227) when left ventricular mass was 
indexed to body surface area (BSA). Table 3.3 shows the characteristics of 
patients with and without left ventricular hypertrophy. The data was normally 
distributed, with similar mean, median and modes, with a typical bell shaped 
curve for all the continuous variables. Multiple regression analysis was 
performed to include all possible determinants of left ventricular mass index: 
age, sex, body mass index (BMI), history of hypertension, previous 
myocardial infarction (MI), diabetes mellitus, ischaemic heart disease, 
systolic blood pressure, creatinine and total cholesterol. This model explained 
only 11.4% of the variation in LVMI, and the factors independently related to 
LVMI were age (standardised β= 0.208, p=0.002), sex (standardised β= 
0.215, p=0.001) and diabetes (standardised β= 0.169, p=0.009).  Notably 
systolic BP was not an independent predictor.  Patients with LVH were 
significantly more likely to be prescribed a beta-blocker (27% vs. 12%, p= 
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0.007), ACE inhibitor (48% vs. 24%, p<0.001) and nitrate (18% vs. 5%, 
p=0.006). 35% of the studied patients (79/227) had a normal LV geometry 
calculated according to body surface area (Figure 3.1). 
 
The association between history of hypertension, clinic BP and the presence/ 
absence of LVH is shown in Figure 3.2. 64% of the study population had a 
history of hypertension (n=145). In this group of patients, 13% were 
normotensive and had LVH. In the group of patients without a history of 
hypertension (n=82), 17% were normotensive and had evidence of LVH. 
Overall, 14% of the entire study population had echo LVH despite a normal 
clinic BP (Figure 3.3). The equivalent data using a lower office BP cutoff 
(<130/80) are shown for completeness (Figure 3.4). 
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3.2 ECHOCARDIOGRAPHIC LEFT VENTRICULAR 
HYPERTROPHY (INDEXED TO HEIGHT2.7) 
The proportion of patients with LVH was 72% (163/227) when left 
ventricular mass was indexed to height2.7. Table 3.4 shows the characteristics 
of patients with and without left ventricular hypertrophy. Multiple regression 
analysis was performed to include all possible determinants of left ventricular 
mass index: age, sex, body mass index (BMI), history of hypertension, 
previous myocardial infarction (MI), diabetes mellitus, ischaemic heart 
disease, systolic blood pressure, creatinine and total cholesterol. This model 
explained only 15.2% of the variation in LVMI, and the factors independently 
related to LVMI were age (standardised β=0.227, p=<0.001), BMI 
(standardised β= 0.274, p<0.001) and diabetes (standardised β= 0.141, 
p=0.029).  Again systolic BP was not an independent predictor.  Patients with 
LVH were significantly more likely to be prescribed a beta-blocker (24% vs. 
8%, p= 0.005), ACE inhibitor (41% vs. 22%, p=0.008), statin (76% vs. 61%, 
p=0.032), diuretic (44% vs. 28%, p=0.035) and nitrate (16% vs. 0%, 
p=0.001). Concentric LVH was the most common geometry pattern (38%, 
86/227) with 23% (52/227) of patients having normal geometry (Figure 3.5). 
 
The association between history of hypertension, clinic BP and the presence/ 
absence of LVH is shown in Figure 3.6. In the group of patients without a 
history of hypertension (n=82), 33% were normotensive and had evidence of 
LVH. Overall, 24% of the entire study population (n=227) had echo LVH 
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despite a normal clinic BP (Figure 3.7).  The equivalent data using a lower 
office BP cutoff (<130/80) are shown for completeness (Figures 3.8).  Even 
using this lower cutoff, 16% of LVH patients had a normal BP, irrespective of 
which LV mass criteria are applied. 
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3.3 AMBULATORY BLOOD PRESSURE (24 HOUR) 
3.3.1 LVH indexed to Body Surface Area 
24 hour ambulatory blood pressure readings were carried out in 64% of the 
LVH patients (73/114) and 51% of the non-LVH patients (58/113). Those 
who underwent this test were randomly chosen purely due to the availability 
of spare 24 hour Blood pressure monitoring equipment, albeit with a bias 
towards performing this test more frequently in patients with LVH than those 
without LVH because the LVH patients were obviously of more interest here.  
 
Mean ambulatory systolic blood pressure was significantly lower in the non-
LVH group compared to the LVH group (Table 3.5). There was no 
significant difference in the mean diastolic blood pressure reading in both 
groups. The percentage of patients with a normal ambulatory BP reading was 
not significantly different in both the LVH and non-LVH group. 40% of the 
patients in the LVH group had a normal 24-hour ABPM reading.  
 
The data for the number of patients in each group in Figure 3.9 were adjusted 
to represent the whole PAD population rather than just the subset who 
received ABPM, taking into account the bias toward measuring ABPM in 
those with LVH. Approximately every 1 in 2 patients in this study had a 
normal ABPM reading. In this normotensive group, 43% of the patients had 
LVH.  In fact, a rough summary of the data in Figure 3.9 is that half of the 
patients had LVH and a somewhat different half had a high BP.  PAD patients 
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fall into four equal groups: one quarter had LVH and a high BP, another two 
quarters had either LVH or a high BP and another quarter had neither LVH 
nor a high BP. 
 
3.3.2 LVH indexed to Height 2.7 
Mean ambulatory systolic blood pressure was significantly lower in the non-
LVH group compared to the LVH group (Table 3.6). There was no 
significant difference in the mean diastolic blood pressure reading in both 
groups. The percentage of patients with a normal 24-hour BP reading was not 
significantly different in both the LVH and non-LVH group. 41% of the 
patients in the LVH group had a normal 24-hour ABPM reading. The data for 
the number of patients in each group in Figure 3.10 were adjusted to 
represent the whole PAD population rather than just the subset who received 
ABPM, taking into account the bias toward measuring ABPM in those with 
LVH. Approximately every 1 in 2 patients in this study had a normal ABPM 
reading. In this normotensive group, 63% of the patients had LVH.  
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3.4 SEVERITY OF PERIPHERAL ARTERIAL DISEASE, 
HISTORY OF ATRIAL FIBRILLATION AND 
MYOCARDIAL INFARCTION IN PATIENTS WITH AND 
WITHOUT LEFT VENTRICULAR HYPERTROPHY 
 
There was no difference in the severity of PAD, in terms of ABPI, in patients 
with or without LVH (Table 3.3 and 3.4).  There was a mean ABPI of 0.68 in 
patients with LVH according to BSA compared to 0.69 in patients without 
LVH. The ABPI was the same (0.69) in patients with and without LVH 
according to height 2.7.  
 
Out of two hundred and twenty seven patients studied, there were fourteen 
(6%) who had atrial fibrillation (AF) on a 12-lead ECG performed during the 
assessment (Table 3.7). The patients with AF had a higher mean LVMI of 
189.2g/m2 compared to 130.7g/m2 in those in sinus rhythm at the time of 
assessment (p<0.001). Despite a higher mean mass, there was no statistical 
difference in percentage of patients with LVH between those patients with or 
without AF (64% V 49%, p=0.279). Unsurprisingly, patients with AF had a 
larger left atrial diameter (4.08cm V 3.34cm, p<0.001), smaller LV ejection 
fraction (58% V 67%, p=0.009) and had a significantly higher BNP 
(195pg/ml V 75pg/ml, p<0.001). Patients who were in AF were less likely to 
have a smoking history (64% V 90%, p=0.003) compared to those in sinus 
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rhythm. All other parameters were similar and in particular, there was no 
difference in either clinic blood pressure or history of hypertension between 
those in AF or sinus rhythm.  
 
Patients with a history of myocardial infarction were more likely to have LVH 
than those without (69% V 47%, p=0.024), although their mean LV mass was 
statistically similar (150.5g/m2 V 131.6g/m2, p=0.059) compared to patients 
with no history of prior MI (Table 3.8). Patients with a history of MI were 
more likely to be male (81% V 59%, p=0.015) and have a lower total 
cholesterol (4.16mmol/L V 4.60mmol/L, P=0.004). This is likely to be 
because more patients with a prior MI were prescribed a Statin (91% V 69%, 
P=0.01). There was no difference in office systolic blood pressure, but 
patients with prior MI had a lower diastolic blood pressure (72mmHg V 
78mmHg, p=0.002). This is likely to be because patients with a prior MI are 
more likely to be prescribed anti-hypertensive agents such as beta blockers 
(38% V 17%, P<0.001), ACE inhibitors (52% V 33%, p=0.046) and calcium 
channel receptor antagonists (53% V 35%, p=0.048). Importantly, there was 
no difference in ejection fraction (65% V 67%, p=0.493) between those with 
and without a history of MI.  
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Table 3.1: Patient characteristics (mean +/-SD) of the 350 subjects 
studied 
 
Variable Mean (SD) 
Males (%) 65.1 
Age (years) 68.9 (9.5) 
BMI (kg/m2) 28.3 (4.6) 
Office systolic BP (mmHg) 147 (21) 
Office diastolic (mmHg) 77 (11) 
Creatinine (μmol/L) 107 (50) 
Total Cholesterol (mmol/L) 4.57 (0.95) 
HDL Cholesterol (mmol/L) 1.42 (0.46) 
History of hypertension (%) 61.4 
History of Type II Diabetes (%) 18.3 
Current smokers (%) 39.1 
Ex-smokers (%) 50.5 
History of ischaemic heart disease (%) 32.9 
Previous MI (%) 16.9 
LVMI 
Males 146.5 (61.7) 
Females 123 (38.7) 
Left Ventricular Ejection Fraction (%) 64.6 (12.1) 
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!
Treated with 
Aspirin 70 
Statin 71.7 
Beta blockers 18 
ACE inhibitors 36.8 
Angiotensin receptor blocker (ARB) 9.7 
Clopidogrel 8 
Calcium Antagonist 38.6 
Nicorandil 4 
Nitrate 13.4 
Diuretic 40.9 
 
BMI – Body Mass Index 
BP – Blood Pressure 
MI – Myocardial Infarction 
LVMI – Left Ventricular Mass Index 
ACE – Angiotensin Converting Enzyme 
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Table 3.2: Patient characteristics classified according to presence or 
absence of M-mode LV mass measurements being obtainable. 
 
 
Variable LVM available 
mean (SD) 
(n=241) 
No LVM available 
mean (SD) 
(n=109) 
P 
value 
Males (%) 63 71 0.183 
Age (years) 68 (10) 70 (9) 0.089 
BMI (kg/m2) 28.2 (4.4) 28.4 (4.8) 0.698 
Clinic systolic BP (mmHg) 147 (21) 147 (23) 0.939 
Clinic diastolic BP (mmHg) 77 (11) 77 (11) 0.872 
Creatinine (μmol/L) 107 (57) 108 (31) 0.811 
Total Cholesterol (mmol/L) 4.52 (0.96) 4.67 (0.94) 0.157 
Ex/current smoker (%) 89 92 0.453 
History of hypertension (%) 63 58 0.407 
D.M. (%) 19 17 0.882 
History of MI (%) 16 18 0.645 
 
BMI – Body Mass Index 
D.M. – Diabetes Mellitus 
MI – Myocardial Infarction
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Table 3.3: Patient characteristics classified according to presence or 
absence of left ventricular hypertrophy indexed to body surface area. 
 
Variable LVH 
mean (n=114) 
No LVH 
mean (n=113) 
P value 
Males %  60 65 0.495 
Age (years) 71 65 <0.001 
BMI (kg/m2) 29.0 27.6 0.014 
ABPI 0.68 0.69 0.806 
Clinic systolic BP (mmHg) 151 143 0.002 
Clinic diastolic BP (mmHg) 76 78 0.123 
History of hypertension (%) 70 58 0.054 
History of type II Diabetes (%) 28 11 0.001 
Previous MI (%) 19 9 0.035 
IHD (%) 42 22 0.002 
Current smokers (%) 31 44 0.040 
BNP (pg/ml) 105 57 0.001 
Creatinine (μmol/L) 107 97 0.010 
Total Cholesterol (mmol/l) 4.47 4.59 0.325 
HDL Cholesterol (moml/l) 1.39 1.44 0.342 
LVMI (g/m2) 
Males 184.3 102.4 <0.001 
Females 148.5 91 <0.001 
LV ejection fraction (%) 66 68 0.216 
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IVS (cm) 1.35 1.00 <0.001 
LVID (cm) 5.10 4.67 <0.001 
PWT (cm) 1.21 0.93 <0.001 
Left atrial diameter (cm) 3.55 3.26 0.036 
 
BMI – Body Mass Index 
MI – Myocardial Infarction 
IHD – Ischaemic Heart Disease 
BNP - B-Type Natriuretic Peptide 
LVMI - Left Ventricular Mass Index  
LV – Left Ventricle 
IVS – Interventricular Septum 
LVID – Left Ventricular Internal Dimension 
PWT – Posterior Wall Thickness 
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Table 3.4: Patient characteristics classified according to presence or 
absence of left ventricular hypertrophy indexed to height 2.7.  
 
Variable LVH 
mean (n=163) 
No LVH 
mean (n=64) 
P value 
Males % (n) 62 63 1.00 
Age (years) 70 64 <0.001 
BMI (kg/m2) 29.0 26.7 <0.001 
ABPI 0.69 0.69 0.947 
Clinic systolic BP (mmHg) 149 143 0.064 
Clinic diastolic BP (mmHg) 76 79 0.051 
History of hypertension (%) 67 56 0.167 
History of type II Diabetes (%) 25 6 0.002 
Previous MI (%) 18 5 0.010 
IHD (%) 40 13 <0.001 
Current smokers (%) 34 47 0.070 
BNP (pg/ml) 93 54 0.016 
Creatinine (umol/L) 112 94 0.042 
Total Cholesterol (mmol/l) 4.54 4.52 0.911 
HDL Cholesterol (moml/l) 1.40 1.46 0.425 
LVMI (height 2.7) 
Males 77.2 41.4 <0.001 
Females 70.3 42 <0.001 
LV ejection fraction (%) 66 68 0.403 
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IVS (cm) 1.27 0.93 <0.001 
LVID (cm) 4.98 4.62 <0.001 
PWT (cm) 1.15 0.88 <0.001 
Left atrial diameter (cm) 3.49 3.10 0.021 
 
BMI – Body Mass Index 
MI – Myocardial Infarction 
IHD – Ischaemic Heart Disease 
BNP - B-Type Natriuretic Peptide 
LVMI - Left Ventricular Mass Index  
LV – Left Ventricle 
IVS – Interventricular Septum 
LVID – Left Ventricular Internal Dimension 
PWT – Posterior Wall Thickness 
 107 
Table 3.5: 24 hour ambulatory blood pressure results classified according 
to presence or absence of LVH (indexed to body surface area) 
Variable LVH mean 
(n=73) 
No LVH mean 
(n=58) 
P value 
24 hour systolic (mmHg) 137 130 0.005 
24 hour diastolic (mmHg) 67 70 0.078 
DT systolic (mmHg) 141 135 0.015 
DT diastolic (mmHg) 71 74 0.027 
NT systolic (mmHg) 131 123 0.005 
NT diastolic (mmHg) 63 64 0.346 
Normal 24 hour BP 
(≤130/80) (%) 
40 52 0.216 
Normal DT reading  
(≤135/85) (%) 
40 50 0.289 
Normal NT reading  
(≤120/70) (%) 
25 42 0.058 
Abnormal 24 hour BP 
 (>135/85) (%) 
52 38 0.116 
Abnormal DT reading 
(>140/90) (%) 
51 31 0.032 
Abnormal NT reading 
(>125/75) (%) 
66 49 0.071 
DT – Day Time 
NT – Night Time 
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Table 3.6: 24 hour ambulatory blood pressure results classified according 
to presence or absence of LVH (indexed to height 2.7) 
Variable LVH mean 
(n=101) 
No LVH mean 
(n=30) 
P value 
24 hour systolic (mmHg) 136 128 0.009 
24 hour diastolic (mmHg) 68 71 0.116 
DT systolic (mmHg) 140 133 0.034 
DT diastolic (mmHg) 71 76 0.012 
NT systolic (mmHg) 130 120 0.007 
NT diastolic (mmHg) 63 64 0.704 
Normal 24 hour BP 
(≤130/80) (%) 
41 60 0.094 
Normal DT reading 
(≤135/85) (%) 
40 60 0.060 
Normal NT reading 
(≤120/70) (%) 
28 50 0.027 
Abnormal 24 hour BP 
(>135/85) (%) 
47 30 0.142 
Abnormal DT reading 
(>140/90) (%) 
45 30 0.206 
Abnormal NT reading  
(>125/75) (%) 
57 40 0.143 
DT – Day Time 
NT – Night Time 
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Table 3.7: Patient characteristics classified according to presence or 
absence of Atrial Fibrillation (AF) on 12 lead ECG 
Variable AF 
mean (n=14) 
No AF 
mean (n=213) 
P value 
Males %  64 62 0.083 
Age (years) 77 68 <0.001 
BMI (kg/m2) 28.2 28.3 0.934 
ABPI 0.62 0.69 0.123 
Clinic systolic BP (mmHg) 149 147 0.705 
Clinic diastolic BP (mmHg) 80 77 0.221 
History of hypertension (%) 71 63 0.546 
History of type II Diabetes (%) 14 20 0.620 
Previous MI (%) 21 14 0.418 
IHD (%) 43 31 0.379 
Smokers (current or ex) (%) 64 90 0.003 
BNP (pg/ml) 195 75 <0.001 
Creatinine (μmol/L) 105.6 107.0 0.932 
Total Cholesterol (mmol/l) 4.54 4.26 0.301 
HDL Cholesterol (mmol/l) 1.42 1.44 0.827 
LVMI (g/m2) 189.2 130.7 <0.001 
LV ejection fraction (%) 58 67 0.009 
LVH (%) 64 49 0.279 
LVID (cm) 5.30 4.85 0.02 
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PWT (cm) 1.08 1.07 0.888 
Left atrial diameter (cm) 4.08 3.34 <0.001 
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Table 3.8: Patient characteristics classified according to History of prior 
Myocardial Infarction (MI) 
Variable MI 
mean (n=32) 
No MI 
mean (n=195) 
P value 
Males %  81 59 0.015 
Age (years) 68 68 0.842 
BMI (kg/m2) 29.7 28.1 0.063 
ABPI 0.72 0.68 0.301 
Clinic systolic BP (mmHg) 142 148 0.102 
Clinic diastolic BP (mmHg) 72 78 0.002 
History of hypertension (%) 66 64 0.825 
History of type II Diabetes (%) 28 18 0.179 
Angina (%) 94 22 0.001 
Smokers (current or ex) (%) 88 89 0.842 
BNP (pg/ml) 85 81 0.856 
Creatinine (μmol/L) 109 107 0.849 
Total Cholesterol (mmol/l) 4.16 4.60 0.004 
HDL Cholesterol (moml/l) 1.32 1.43 0.182 
LVMI (g/m2) 150.5 131.6 0.059 
LV ejection fraction (%) 65 67 0.493 
LVH (%) 69 47 0.024 
LVID (cm) 5.29 4.81 <0.001 
PWT (cm) 1.09 1.07 0.740 
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Left atrial diameter (cm) 3.67 3.38 0.154 
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Figure 3.1: Left ventricular geometry in the studied population, using left 
ventricular mass indexed to body surface area 
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Figure 3.2: Association between history of hypertension, clinic BP 
(normal clinic BP <140/90) and presence or absence of LVH (indexed to 
BSA) in this study population 
 
 
A History of Hypertension, High Clinic BP, LVH 28% 
B History of Hypertension, High Clinic BP, No LVH 21% 
C History of Hypertension, Normal Clinic BP, LVH 8% 
D History of Hypertension, Normal Clinic BP, No LVH 7% 
E No History of Hypertension, High Clinic BP, LVH 9% 
F No History of Hypertension, High Clinic BP, No LVH 9% 
G No History of Hypertension, Normal Clinic BP, LVH 6% 
H No History of Hypertension, Normal Clinic BP, No LVH 12% 
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Figure 3.3 Association with Clinic Blood Pressure and presence or 
absence of LVH (indexed to BSA) in the study population. 
 
 
 116 
Figure 3.4: Association between history of hypertension, clinic BP 
(normal clinic BP <130/80) and presence or absence of LVH (indexed to 
BSA) in this study population 
 
 
 
A History of Hypertension, High Clinic BP, LVH 31% 
B History of Hypertension, High Clinic BP, No LVH 26% 
C History of Hypertension, Normal Clinic BP, LVH 4% 
D History of Hypertension, Normal Clinic BP, No LVH 3% 
E No History of Hypertension, High Clinic BP, LVH 11% 
F No History of Hypertension, High Clinic BP, No LVH 15% 
G No History of Hypertension, Normal Clinic BP, LVH 4% 
H No History of Hypertension, Normal Clinic BP, No LVH 6% 
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Figure 3.5: Left ventricular geometry in the studied population, using left 
ventricular mass indexed to height 2.7 
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Figure 3.6: Association between history of hypertension, clinic BP 
(normal clinic BP <140/90) and presence or absence of LVH (indexed to 
height 2.7) in this study population 
 
 
 
 
A History of Hypertension, High Clinic BP, LVH 36% 
B History of Hypertension, High Clinic BP, No LVH 12% 
C History of Hypertension, Normal Clinic BP, LVH 12% 
D History of Hypertension, Normal Clinic BP, No LVH 4% 
E No History of Hypertension, High Clinic BP, LVH 12% 
F No History of Hypertension, High Clinic BP, No LVH 5% 
G No History of Hypertension, Normal Clinic BP, LVH 12% 
H No History of Hypertension, Normal Clinic BP, No LVH 7% 
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Figure 3.7 Association with Clinic Blood Pressure and presence or 
absence of LVH (indexed to Height 2.7) in the study population. 
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Figure 3.8: Association between history of hypertension, clinic BP 
(normal clinic BP<130/80) and presence or absence of LVH (indexed to 
height 2.7) in this study population 
 
 
 
A History of Hypertension, High Clinic BP, LVH 43% 
B History of Hypertension, High Clinic BP, No LVH 14% 
C History of Hypertension, Normal Clinic BP, LVH 5% 
D History of Hypertension, Normal Clinic BP, No LVH 2% 
E No History of Hypertension, High Clinic BP, LVH 17% 
F No History of Hypertension, High Clinic BP, No LVH 9% 
G No History of Hypertension, Normal Clinic BP, LVH 7% 
H No History of Hypertension, Normal Clinic BP, No LVH 3% 
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Figure 3.9: Association between ambulatory BP reading and the presence 
or absence of LVH (indexed to BSA) in the study population. 
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Figure 3.10: Association between ambulatory BP reading and the 
presence or absence of LVH (indexed to Height 2.7) in the study 
population. 
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The results of this study suggest a very high prevalence (50-72%) of echo 
LVH in patients with peripheral arterial disease (i.e. 50% when indexed to 
BSA and 72%  when indexed to height 2.7).  Given what we know about the 
prognosis of LVH it is extremely likely that the high rate of cardiac death in 
PAD patients is attributable to some extent to this high prevalence of LVH.  
My other main finding is that blood pressure is an insensitive way of 
identifying which PAD patients have LVH since an office BP of <140/90 is 
found in 27-33% of all PAD patients with LVH depending on which LVH 
criteria are applied.  Similarly a normal 24 hour BP is seen in 44-46% of all 
PAD patients with LVH. 
 
Left ventricular hypertrophy is an independent predictor of cardiovascular 
death that is currently underestimated in current practice.  In the only 
comparative study, the independent relative risk of LVH was 2.4 whereas the 
relative risk for multivessel disease was only 1.6 and for LV dysfunction was 
only 2.0 (7).  This study in CAD patients by Liao suggests that LVH is likely 
to be the strongest risk factor in vascular patients.  The importance of 
detecting and treating LVH is underscored by the fact that treatment 
regression of LVH independent of BP control is highly effective in reducing 
cardiac risk (114).  Indeed, complete regression of LVH appears to reduce the 
risk of future cardiovascular events to normality (16).   
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To the best of my knowledge, this study is the first ever to look at LVH 
prevalence in PAD patients per se.  The nearest previous study recruited 
hypertensive individuals with coronary disease and found that the added 
presence of PAD as a third disease increased the LVH prevalence from 46% 
to 75% (33).  The fact that echo LVH is an extremely common finding in this 
study (at least one in two patients have this condition) suggests that current 
clinical practice may be ignoring what is arguably the biggest independent 
risk factor in a group of patients who need intensive secondary prevention.  
Since treating LVH is so effective, it now seems that detecting and treating 
LVH in PAD patients could be a new worthwhile goal with a strong chance of 
being able to reduce the currently high rate of cardiac death in PAD patients.  
It could theoretically also reduce perioperative cardiac events when the PAD 
patients need surgery. 
 
In general, LVH may not get the prominence it deserves because of two 
misconceptions.  The first misconception is the assumption that LVH only 
occurs in patients with Hypertension.  This is not the case in normal 
populations and we have now found the same for PAD patients.  For example, 
in Framingham, echo LVH occurred in 33% of men and 49% of women over 
the age of 70 years with a systolic BP 125-139 mmHg (10).  In the Strong 
Heart Study, systolic blood pressure was weakly associated with LV mass and 
nearly 50% of LV mass variability remained unexplained (100).  In this study, 
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a nonhypertensive office BP was found in 27-33% (depending on which LVH 
criteria are used) of all PAD patients with LVH. 
 
It is worth noting that in this study LVH was indeed significantly associated 
with a higher office BP (151 mmHg vs 143 mmHg) and a higher 24 hr BP 
(137 vs 130 mmHg).  However, BP was not an independent predictor in the 
multiple regression analysis.  In addition, what is relevant for clinical practice 
is that 14%-24% of this study population overall had LVH and a 
nonhypertensive office BP and 22-33% of this population had LVH and a 
normal 24 hour BP.  Thus, blood pressure can be used in PAD patients to 
identify LVH but a high BP produces a lot of false positives as far as LVH is 
concerned and a low BP produces a lot of false negatives.  Thus, using blood 
pressure to predict presence of LVH in PAD patients would miss a high 
proportion of these patients. 
 
A unique feature of this study is that ambulatory BP was measured in addition 
to office BP.  It is somewhat surprising that a normal 24 hour BP missed even 
more LVH than an office BP.  Previous studies in hypertension suggested the 
opposite (207-209).  This may be because the aetiology of LVH in PAD 
patients is more complex and less dependent on the single issue of BP than it 
is in hypertensive patients, although this is refuted somewhat by the fact that 
in this study the mean BP difference between LVH and non LVH was of the 
same magnitude for office and 24 hour BPs.  Another possibility is that the 
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optimum cutoff value for 24 hr BP to detect LVH may be different in PAD 
than in hypertension, although again this was not apparent in these data.  
However, the key point for clinical practice is that it has previously been 
suggested that an abnormal 24 hr BP should alert the clinician to look for 
echo LVH (210, 211).  Although this may work well for hypertension, it does 
not appear so in PAD patients since a normal 24 hr BP (130/80 mmHg) would 
miss 44-46% of LVH in PAD.  In fact, Figures 3.3 and 3.4 illustrates well 
the dissociation between LVH and 24 hr BP in that one quarter of all PAD 
patients had both abnormalities, two more quarters had one abnormality 
without the other and the final quarter had neither abnormality. 
 
The second general misconception regarding LVH leading to it being 
relatively ignored is that medications that attenuate the Renin-Angiotensin-
Aldosterone-System and reduce blood pressure to target levels “cure” LVH.  
In fact, the high prevalence of LVH in this population despite 46% of them 
taking either an ACE inhibitor or an ARB tends to refute this.  A more 
compelling argument that modulation of the RAAS does not cure LVH is that 
Losartan and Ramipril only reduced cardiovascular events by 14-25% in the 
LIFE and HOPE trials, suggesting that Angiotensin-II withdrawal is not a 
cure for LVH (57, 123).  This leaves a lot of room for further improvement in 
treating LVH over and above AII withdrawal therapy.  Therefore, it is 
appropriate to conclude that ACE inhibitors/ARB may reduce LVH but do not 
fully abolish it.  There may be some reluctance to prescribe ACE inhibitors or 
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ARBs in PAD patients because they have a high incidence of coincidental 
renovascular disease.  In fact, only 38% and 8% of PAD patients in this thesis 
were prescribed ACE-inhibitors or ARBs, respectively. 
 
Various methods exist with regards to defining echocardiographic LVH.  The 
indexation of LV mass to body height 2.7 appears to detect obesity-
independent and obesity-related LVH equally well (12).  For this reason, I 
indexed LV mass to BSA and body height 2.7 and found a difference of 22% in 
LVH prevalence between the two.  Both methods have been prognostically 
validated and one recent study showed that LV mass indexed to height 2.7 
carried a higher cardiac risk when compared to indexation of LV mass to 
BSA (relative risk of 3.3 versus 2.6 respectively) (88, 98).  The main finding 
is not dependent on the LV mass indexation used because LVH is worryingly 
high (50% or 72%) regardless of whichever indexation method is employed. 
 
This study has some limitations: 
 
Firstly, 31% of the patients screened did not have adequate echocardiographic 
images to allow M-mode measurements of left ventricular dimensions to be 
made.  This appears to be a common weakness in all echocardiographic 
studies but it may be larger here because this study PAD patient population 
had a very high incidence of smoking (current smokers 39%, ex-smokers 
51%).  Smoking related COPD makes it hard to obtain adequate echo images 
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(11, 16).  Nevertheless, there was no significant differences in terms of 
baseline characteristics in the group between those where an M-mode LV 
mass was obtainable as opposed to those without an M-mode LV mass which 
allows us to conclude that my echo sample was truly representative of the full 
PAD population.   
 
Secondly, 17% of the study population had a previous history of MI, which 
may have contributed to the high prevalence of abnormal LV geometry, 
although not in a statistically independent way.  Having said this, previous 
MIs are also typical of a PAD population.   
 
Thirdly, not all of my patients were at target Blood Pressure, but this appears 
to be a common scenario (212).  This makes this study representative of the 
real world, even if not of the ideal world.  It would be of interest to know how 
much renovascular disease contributes to BP in PAD patients but there is no 
easy screening test for it that I could have applied in such a large group of 
patients as here.   
 
Overall, all three of the “limitations” described above make this study truly 
representative of real world PAD patients which could be viewed as strengths 
rather than weaknesses for an epidemiology type study such as this.  
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Fourthly, there was no control group to compare prevalence of LVH and 
blood pressure.  Although, Framingham and other population studies supply 
this general information anyway (7, 10, 67, 91, 102, 121, 157, 213-215).  I 
preferred to focus my efforts on studying a larger group of PAD patients than 
studying fewer PAD patients but adding controls. Finding controls matched 
for everything with the PAD cohort would have been difficult and time 
consuming. 
 
Intra-observer variability was not formally assessed in this study, which may 
be interpreted as a limitation. Intra-observer (and inter-observer) variability 
were calculated in a previously published study involving 
echocardiographically defined LVH in patients with cardiovascular disease; 
and was found to be excellent (216). In this study I randomly reviewed fifty 
echocardiogram studies of patients with angiographically proven coronary 
artery disease who underwent a prior echocardiogram. A clinical risk score 
was calculated using various parameters to predict presence of 
echocardiographically determined LVH. This was validated in my PVD 
patient cohort. In this published study a Bland Altman plot showed a high 
level of agreement between myself and the other operator. The intra- and 
inter-observer agreement was 98%. No formal calculation of intra-observer 
variability was carried out for this group of patients in this Thesis. I am 
unable to retrospectively reanalyze the images for intra-observer variability 
calculations as they were stored on VHS tapes, which have subsequently been 
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destroyed. However, taking the excellent agreement from the above published 
study and the rigorous way I recorded and analysed the echo images, one 
would anticipate similarly good reproducibility.  
 
Once identified, the question arises as to how we should regress LVH in these 
patients.  This firstly involves better achieving of target BPs along with the 
lowering of target BPs, as recommended by the JBS2 guidelines (217).  This 
could also mean the achievement of even lower than conventional BP targets 
in those with LVH (e.g. systolic BP of 120 mmHg or lower) or even an 
individualised BP target level that ensures full LVH regression in that 
individual.  In the study by Simpson et al (2010) from the University of 
Dundee, a 9mmHg reduction in blood pressure from a normal baseline blood 
pressure (mean 122mmHg systolic) significantly reduced LV mass in a group 
of patients with LVH and normal office blood pressure (133). The meta-
analysis by Law et al (2009) of blood pressure reduction showed that 
lowering systolic BP by 10mmHg reduces CHD events by a quarter and 
stroke by a third, regardless of drug used, presence or absence of target organ 
damage or blood pressure before treatment (218). Indeed, the relative risk 
reduction in events was similar across all levels of blood pressure down to 
110/70 mmHg; below which there was too few data to make statistical 
conclusions (218). A third possibility is the addition of an aldosterone 
antagonist such as spironolactone or eplerenone.  In the 4E study, this reduced 
LV mass on top of an ACE inhibitor despite the final systolic BP only being 5 
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mmHg lower (139 to 134 mmHg) (219).  A fourth possibility which has been 
shown already to regress LV mass in normotensive patients is copper 
chelation with trientine (220-222).  A new possibility to regress LVH studied 
recently in Dundee is allopurinol which reduces oxidative stress and LV 
afterload. Further studies should now address these possible ways of 
regressing LV mass in LVH patients with PAD (223-225). 
 
In summary, the results of this study have major implications for patients with 
PAD.  Firstly, the prevalence of LVH in PAD is exceedingly high.  Secondly, 
normotensive LVH is not uncommon in stable PAD patients.  Although a 
higher BP does point to LVH, there is a lot of overlap such that a normal 
office BP still occurs in 27%-33% of all PAD patients with LVH.  A normal 
24 hour BP occurs in even more (44-46%) PAD patients with LVH.  Future 
studies should now address whether detecting and regressing LVH in PAD 
patients would be a new cost effective way to reduce the unacceptably high 
rate of cardiac death in such patients.  Potentially it might also reduce 
perioperative cardiac events. 
 
In the United Kingdom, more than 100 000 people are newly diagnosed with 
PAD each year. Symptomatic PAD confers a poor quality of life and is a 
major marker for future cardiovascular events with a worse prognosis than MI 
or breast cancer (6). As a result, the majority die from cardiovascular causes 
such as MI, stroke or arrhythmia. Strenuous efforts need to be directed 
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towards helping physicians, and General Practitioners in particular, highlight 
and address risk factor modification. Interventions include improved diet and 
exercise, smoking cessation programs, drug therapy, and, where necessary, 
blood pressure and glucose regulation.  
 
As this study demonstrates, diagnosis and treatment of LVH in this group of 
patients, could potentially prove exceedingly effective in reducing 
cardiovascular morbidity and mortality. 
Future work needs to be directed to seeing if major risk factor modification 
and aggressive prescribing of RAAS modulators improves the prognosis of 
these patients with a high cardiovascular burden and morbidity and mortality. 
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Appendix I: Example of Initial 
Letter inviting patient to take part 
in study!
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«Forename»!«Surname»!«Address_1»!«Address_2»!«Address_3»!«Post_Code»! ! ! ! ! ! ! ! «Letter»!!Dear!«Sex»!«Surname»,!!!You!attended!an!appointment!at!the!Vascular!Laboratory!in!the!Hospital!this!year!to!test!the!blood!flow!in!your!legs.!We!are!currently!undertaking!an!important!study!with!Professor!Peter!Stonebridge,!Consultant!Vascular!Surgeon!and!Professor!Allan!Struthers,!Professor!of!Cardiovascular!Medicine!involving!people!who!have!attended!the!Vascular!Laboratory.!I!have!attached!an!information!sheet!for!you!to!read!which!will!give!you!more!information!about!the!study!and!why!we!are!doing!it.!!This!study!will!not!interfere!with!the!care!you!are!receiving!from!Professor!Stonebridge!or!his!colleagues!in!Ninewells!Hospital.!We!will!reimburse!you!fully!for!any!travel!expenses!you!incur!attending!your!study!appointment.!If!you!require!transport!to!take!you!to!your!study!appointment!and!back!I!can!organise!this!for!you!and!we!will!pay!for!it!in!full.!!I!would!be!most!grateful!if!you!would!return!the!tear6off!slip!below!to!me!in!the!stamped!addressed!envelope!provided.!Alternatively,!you!can!telephone!me!on!01382!496355!for!more!information.!!Yours!Sincerely,!!Dr!Gary!A!Wright!!
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Please&fill&out&with&telephone&number,&detach&slip&and&return&in&envelope&
provided!I!would!like!an!appointment!for!your!study! !  !I!would&not!like!an!appointment!for!your!study!  !I!would!like!more!information!on!the!study! !  !!!«Forename»!«Surname»!Telephone!Number……………………………………….!
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Appendix II: Example of Reminder 
Letter inviting patient to take part 
in study 
!
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«Forename»!«Surname»!«Address_1»!«Address_2»!«Address_3»!«Post_Code»! ! ! ! ! ! ! ! 10!November!2014!!Dear!«Sex»!«Surname»,!!!You!may!remember!I!sent!you!a!letter!(copy!attached)!inviting!you!to!take!part!in!a!study!involving!people!like!yourself!with!poor!circulation!in!the!legs!and!feet.!I’m!not!sure!if!you!received!the!letter!or!not,!if!you!have!I!hope!you!don’t!mind!me!sending!another!one.!The!study!will!involve!only!one!visit!which!will!take!approximately!1!to!1!½!hours.!I!have!attached!an!information!sheet!about!the!study!which!you!can!read!at!your!leisure.!!!Could!you!please!fill!in!the!tear!off!slip!below!to!indicate!if!you!wish!to!take!part!in!the!study!or!not!and!if!you!would!like!me!to!call!you!with!more!information.!!I!look!forward!to!hearing!from!you.!!Yours!Sincerely,!!Dr!Gary!A!Wright!!
Please&fill&out&with&telephone&number,&detach&slip&and&return&in&envelope&
provided!I!would!like!an!appointment!for!your!study! !  !I!would&not!like!an!appointment!for!your!study!  !I!would&like&you&to&call&with&more&information!  !!!«Forename»!«Surname»!Telephone!Number……………………………………….!
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Appendix III: Example of Letter 
detailing date of visit and directions 
to patients!
 162 
Forename!Surname!Address!Address!«Address_3»!«Post_Code»! ! ! ! ! ! ! 10!November!2014!!!
LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH 
PERIPHERAL ARTERY DISEASE: THE FIRST STEPS IN 
ADDRESSING A PREVIOUSLY IGNORED BUT TREATABLE 
CULPRIT. !Dear!Name,!!Further!to!my!previous!letter!your!Date!to!attend!the!Department!of!
Clinical!Pharmacology!for!your!appointment!is!(it!will!take!approximately!one!hour):!!
«Day»!«Date»«th»!«Month»!2004!at!«Time»!!For!the!department!of!Clinical!Pharmacology!you!turn!left!after!the!Metropole!Café!and!go!past!wards!1&2,!3&4!and!5&6!right!to!the!end!of!the!corridor.!Go!through!to!the!Department!and!ask!for!me,!if!you!can!not!find!anyone!then!ask!the!secretaries!in!the!Department!and!they!will!come!and!get!me.!!!Could!you!please!bring!with!you!a!list!of!your!current!medication.!!If!you!have!any!questions,!want!to!change!your!appointment!or!require!transport!then!please!feel!free!to!phone.!I!look!forward!to!seeing!you!then.!!Yours!Sincerely,!!!
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Dr!Gary!A!Wright!Clinical!Research!Fellow!Department!of!Clinical!Pharmacology!Level!7!Ninewells!Hospital!01382!496355!
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Appendix IV: Consent Form 
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Left Ventricular Hypertrophy in Patients with Peripheral Arterial Disease:  
The First Steps in Addressing a Previously Ignored but Treatable Culprit. !
CONSENT FORM !
NB. This form must be completed by the research subject in the presence of someone 
with knowledge of the research designed by the principal investigator. This may be a 
doctor, nurse, clinical research assistant or other member of the research team who must 
countersign the form as witness to the subject’s signature !
Please tick (!) appropriate box !Have!you!read!and!understood!the!Subject!Information!Sheet?! !! ! ! Yes!"! No!"!!Have!you!been!given!an!opportunity!to!ask!questions!and!further!discuss!this!study?! ! Yes!"! No!"!!Have!you!received!satisfactory!answers!to!all!of!your!questions?! !! ! ! Yes!"! No!"!!Have!you!now!received!enough!information!about!this!study?! !! ! Yes!"! No!"!!Who!have!you!spoken!to?! Dr/Mr/Mrs/Miss!!………………………………………………………!!Do!you!understand!that!your!participation!is!entirely!voluntary?! !! ! ! Yes!"! No!"!!Do!you!understand!that!you!are!free!to!withdraw!from!this!study:!!At!any!time?! ! ! ! ! ! ! ! !! ! Yes!"! No!"!!Without!having!to!give!a!reason!for!withdrawing?! ! ! !! ! Yes"! No!"!!Without!this!affecting!your!present!or!future!medical!care?! ! !! ! Yes!"! No!"!!Do!you!agree!that!your!records!in!this!research!and!supporting!medical!records!be!made!available!for!inspection!by!monitors!from:!!NHS!Tayside!monitors?! ! ! ! ! ! !! ! ! Yes!"! No!"!Regulatory!authorities?! ! ! ! ! ! !! ! ! Yes!"! No!"!!
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Do!you!agree!to!take!part!in!this!study?! ! ! ! !! ! ! Yes!"! No!"!!Do!you!agree!to!any!blood!used!in!this!study!being!!retained!for!use!in!future!research?! ! ! ! ! !! ! Yes!"! No!"!! !!Subject’s!signature!…………………………………………….! Date!………………….…………!!Subject’s!name!in!block!capital!letters!………………………………………………………………!!Telephone!contact!(Subject)!!…………………………….(Home)!!!…………………………..(Work)!!Signature!witnessed!by!……………………………………………! Date!.……………………………!!Witness!name!in!block!capital!letters!!!!…………………………………………………………….!
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Appendix V: Echo Reporting Form 
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GAW003!Left!Ventricular!Hypertrophy!in!patients!with!peripheral!
vascular!disease:!the!first!steps!in!addressing!a!previously!ignored!
but!treatable!culprit.!
!
ECHOCARDIOGRAPHY!!Patient!Number:____________!!Date!of!Examination:______________!!Tape:_______________!!!!
1.!Measurements!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! ! Mean!of!3!IVSd! ! ______cm! ! Fractional!Shortening!%!!!LVIDd! ! ______cm!PWTd! ! ______cm!IVSs! ! ______cm!LVIDs! ! ______cm! ! LV!Mass!Index!(g/m2)!PWTs! ! ______cm!LA!Size! ______cm!Aortic!Root! ______cm!!!
2.!Modified!Simpsons!Ejection!Fraction!Mean!EDV!4ch!(ml)________!Mean!ESV!4ch!(ml)!________! ! Ejection!Fraction!%!Mean!EDV!2ch!(ml)!________!
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Mean!ESV!2ch!(ml)!________!
GAW003!Left!Ventricular!Hypertrophy!in!patients!with!peripheral!
vascular!disease:!the!first!steps!in!addressing!a!previously!ignored!
but!treatable!culprit.!!Patient!Number:________!!
3.!LV!Diastolic!Assessment!! Mean!E! !A! !E/A!Ratio! !Deceleration!Time! !IVRT! !!
4.!Subjective!Assessment!of!LV,!Valves!and!Right!Heart!!!
 
